CANCER IN IDAHO - 2000

A Publication of the Cancer Data Registry of Idaho



A Program of the Idaho Hospital Association



Editors:

Christopher J. Johnson, MPH, Epidemiologist Stacey L. Carson, RHIT, CTR, Vice President and Executive Director/CDRI

Contributors:

Denise Jozwik, RHIT, CTR, Assistant Director Jessica Shew, CTR, Cancer Data Controller

December 2001

CANCER DATA REGISTRY OF IDAHO
P.O. Box 1278
Boise, Idaho 83701-1278
208-338-5100 ext 213 (phone)
208-338-7800 (FAX)
http://www.idcancer.org

PREFACE

"Cancer in Idaho - 2000," the twenty-fourth annual report of the Cancer Data Registry of Idaho (CDRI), contains data on cancer cases diagnosed during 2000 among Idaho residents. These data can be used by public health officials, hospital administrators, physicians, and others to effectively plan services, prioritize health resource allocations, develop and measure prevention and intervention strategies, and identify high risk populations within the state of Idaho.

ACKNOWLEDGMENTS

The Idaho Hospital Association (IHA) contracts with, and receives funding from, the Idaho Department of Health and Welfare, Division of Health, to provide a statewide cancer surveillance system.

The statewide cancer registry database is a product of collaboration among many report sources including: hospitals, physicians, surgery centers, pathology laboratories, and other states in which Idaho residents are diagnosed and/or treated for cancer. Their cooperation in reporting timely, accurate, and complete cancer data is acknowledged and sincerely appreciated.

CDRI would also like to thank the Idaho Bureau of Vital Records and Health Statistics, the Bureau of Clinical and Preventive Services, the Bureau of Health Promotion, and the Bureau of Environmental Health and Safety of the Idaho Department of Health and Welfare, Division of Health, for their continued partnership in using CDRI data as a tool in cancer control and prevention.

This publication was supported by Cooperative Agreement Number U75/CCU010673-07 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.

SUGGESTED CITATION:

Johnson CJ, Carson SL. *Cancer in Idaho, 2000.* Boise, ID: Cancer Data Registry of Idaho; December 2001.

COPYRIGHT INFORMATION:

All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

TABLE OF CONTENTS

	Page
1.	Forewordi
2.	Preface and Acknowledgments ii
3.	Background
	Introduction to the Cancer Data Registry of Idaho
4.	Section I - 2000 Summary on All Sites Combined and 24 Most Common Sites .9 All sites .10 Bladder. .12 Brain .14 Breast .16 Cervix. .18 Colon (excluding rectum) .20 Endometrium .22 Esophagus .24 Hodgkin's Lymphoma .26 Kidney .28 Larynx .30 Leukemia .32 Liver .34 Lung .36 Melanoma of Skin .38 Myeloma .40 Non-Hodgkin's Lymphoma .42 Oral Cavity and Pharynx .44 Ovary .46 Pancreas .48 Prostate .50 Rectum .52 Stomach .54 Testis .56 Thyroid .58

TABLE OF CONTENTS

5.	Section II - State of Idaho - 2000 Incidence Data by Site and Gender 61
6.	Section III - State of Idaho - 2000 Mortality Data by Site and Gender 65
7.	Section IV - 2000 Age-specific Incidence Rates per 100,000 Population by Site and Gender
8.	Section V - 2000 Observed vs. Expected Numbers by Health District 73 All Sexes
9.	Section VI - Risks of Developing and Dying from Cancer77All Sites, Invasive78Female Breast/Prostate79Colon/Rectal Cancer80Melanoma81
10.	References
11.	Appendices
	A. Standard Site Analysis Categories

BACKGROUND

Introduction to the Cancer Data Registry of Idaho (CDRI)

Purpose of the Registry

Population-based cancer registries are essential for assessing the extent of cancer burden in a specified geographic area. The Cancer Data Registry of Idaho (CDRI) is a population-based cancer registry that collects incidence and survival data on all cancer patients who reside in the state of Idaho or who are diagnosed and/or treated for cancer in the state of Idaho. The goals of the CDRI are to:

- determine the incidence of cancer in the state of Idaho with respect to geographic, demographic, and social characteristics:
- monitor trends and patterns of cancer incidence over time;
- identify high risk populations;
- provide a database and serve as a resource in conducting epidemiologic studies; and
- provide data to assist public health officials, hospital administrators, and physicians to effectively plan services, prioritize health resource allocations and develop and measure prevention and intervention strategies.

History and Funding of the Registry

CDRI was established in 1969 and became population-based in 1971. The Idaho State Legislature has provided guidelines for the establishment, requirements, and funding of the statewide cancer registry. The operations of the registry are mandated by Idaho Code 57-1703 through 57-1707. Funding is appropriated in Idaho Code 57-1701 and 63-2520, which delineates one percent of the cigarette tax to be dedicated to fund the statewide cancer

registry. Additional funding has been awarded to CDRI from the Centers for Disease Control and Prevention (CDC) to enhance timely, complete and accurate data collection, computerization, and reporting of reliable data.

Collection of Data

Each Idaho hospital, outpatient surgery center, and pathology laboratory is responsible for the complete ascertainment of all data on cancer diagnoses and treatments provided in its facility within six months of diagnosis. Sources for identifying eligible cases include:

- hospitals,
- outpatient surgery centers,
- private pathology laboratories,
- free-standing radiation centers,
- physicians (for patients not receiving cancer diagnoses and/or treatment in the above sources),
- death certificates, and
- other state cancer registries reporting an Idaho resident with cancer (as negotiated).

When a cancer case is reported from more than one source, the information is consolidated into one record. Reported cases contain the following data:

- patient demographics (including geographic place of residence at time of cancer diagnosis);
- description of cancer (including date of diagnosis, primary site, metastatic sites, histology, extent of disease, etc.);
- first course treatment; and
- follow-up data for purposes of calculating survival rates.

Primary site, behavior, grade, and histology were coded according to the "International Classification of Diseases for Oncology, 2nd edition." Stage of disease variables were coded using "SEER's Summary Staging Guide" and "AJCC Manual for Staging of Cancer, 5th edition." All other variables were coded following the rules of the North American Association of Central Cancer Registries, the SEER program, and the American College of Surgeons. 4-6

Reportable Cases

All in-situ or malignant neoplasms are reportable to CDRI. The database includes all cases of carcinoma, sarcoma, melanoma, lymphoma, and leukemia, diagnosed by histology/ cytology, radiology, laboratory testing, clinical observation, and autopsy.

Also reportable are benign tumors of the brain, meninges, pineal gland, and pituitary gland.

Basal and squamous cell carcinomas of the skin are excluded except when occurring on a mucous membrane or if the AJCC stage group is II, III, or IV.

Under Idaho Code and as recommended by the North American Association of

Central Cancer Registries, cervix in-situ cases are not currently reportable.

Confidentiality of Data

Idaho state law ensures the protection of confidential data and restricts the release of identifying data. Only aggregate data are published. The same law protects report sources from any liability for reporting confidential data to CDRI. Persons with access to confidential data are required to sign a pledge of confidentiality and are subject to penalty if they, through negligence or willful misconduct, disclose confidential data.

Quality Assurance

To assure validity and reliability of data presented, CDRI has many mechanisms in place to check data for quality and completeness. CDRI uses EDITS software which has standard edits using algorithms that check the content of data fields against an encoded set of acceptable possible contents and flags the acceptability of coded data. Edits include field edits, interfield edits, and inter-record edits. Edits check for unlikely sex/site, site/histology, or site/age combinations. In addition to computerized edits, each case is manually reviewed for errors.

Records are also routinely checked for duplicate entries. Duplicate case checking is performed both manually and electronically using various methodologies.

Idaho data have qualified for inclusion in all volumes of NAACCR's publication of "Cancer Incidence in North America." In order to be included, states must meet standards for quality and completeness.

Executive Summary

Data Presentation

This report is comprised of five sections. <u>Section I</u> focuses on the 24 most common cancer sites and all sites combined and presents age-adjusted incidence rates, numbers of cases, numbers of deaths, counts by county, stage of disease at time of diagnosis, risk factors, special notes, age-adjusted incidence rate comparisons by health district, and age-specific rates by gender. <u>Section II</u> depicts incidence data by site and gender for invasive and in-situ cases. <u>Section III</u> depicts mortality data by site and gender. <u>Section IV</u> contains a table of age-specific cancer rates, per 100,000, by site and gender. <u>Section V</u> contains a table of observed versus expected numbers of cancer cases by health district. <u>Section VI</u> contains tables of age-specific risks of developing and dying from cancer for males and females.

Population Description

The population of the state of Idaho in 2000 was 1,293,953 (648,660 males and 645,293 females). Population figures were obtained from the U.S. Bureau of the Census.⁷ Idaho is comprised of 44 counties grouped into seven health districts. The composition of the health districts, as well as their population estimates by gender as used in this report, are shown below:

Health District	Counties	<u>Male</u>	<u>Female</u>
District 1	Benewah, Bonner, Boundary, Kootenai, Shoshone	88,773	89,560
District 2	Clearwater, Latah, Lewis, Idaho, Nez Perce	51,019	49,514
District 3	Adams, Canyon, Gem, Owyhee, Payette, Washington	95,257	96,040
District 4	Ada, Boise, Elmore, Valley	174,327	170,028
District 5	Blaine, Camas, Cassia, Gooding, Jerome, Lincoln, Minidoka, Twin Falls	81,469	80,928
District 6	Bannock, Bear Lake, Bingham, Butte, Caribou, Franklin, Oneida, Power	78,011	78,895
District 7	Bonneville, Clark, Custer, Fremont, Jefferson, Lemhi, Madison, Teton	79,804	80,328

Descriptive Summary by Gender and Race and Ethnicity

The data presented in this report cover those cases diagnosed among Idaho residents between January 1, 2000, and December 31, 2000. In this time frame, there were 5,756 cases of cancer diagnosed among Idaho residents (2,978 among males and 2,777 among females; 1 other/missing). By race and ethnicity, there were 5,594 cases among non-Hispanic whites, 85 among Hispanic whites, 4 cases among Blacks, 8 cases among Native Americans, 31 cases among Asians/Pacific Islanders, and 6 cases among other races. Race was missing for 23 cases, and 5 cases among whites had unknown ethnicity. The majority of cases with missing race and/or ethnicity were reported by out-of-state sources. The number of cancer cases treated in outpatient settings and reported only by pathology laboratories has increased over the last several years. Many of such cases are reported with race missing, causing tabulations of cases by race to be skewed. CDRI is actively working to improve the data quality of cases reported by pathology laboratories only.

Trends

There was an increase of 359 cases from 1999 to 2000 (as of one year after close of calendar year). This was one of the largest single-year increases in cancer incidence in the history of the Cancer Data Registry of Idaho. Cancer sites with notable increases from 1999 to 2000 were lung, melanoma (in-situ), oral cavity and pharynx, and prostate. While lung and oral cavity and pharynx cancer counts increased over 1999 levels, the incidence rates are similar to recent rates earlier than 1999. The number of in-situ melanoma cases is 65% higher than for any previous year. The prostate cancer incidence rate is the highest it has been since the spike in prostate cancer rates in 1990-1993 due to prostate-specific antigen (PSA) screening. However, the increase in rates was limited to Health Districts 2, 4, 5, and 7.

Technical Notes

Age-adjusted Incidence Rates

Age-adjusted incidence rates published within this report were adjusted using the direct method and standardized to the age distribution of the 2000 U.S. population (see Appendix B for the 2000 U.S. standard population). Incidence rates represent the average number of new cases diagnosed annually per 100,000 persons. Age adjustment allows rates from one geographic area to be compared with rates from other geographic areas that may have differences in age distributions. Any observed differences in age-adjusted incidence rates between populations are not due to differing age structures.

Because the 2000 U.S. standard population was used to age-adjust rates, the age-adjusted rates published in this report are not comparable with age-adjusted rates published in CDRI annual reports for years prior to 1999.

The computation of rates requires reliable estimates of the population at risk by five-year age groups and gender during the time period being studied. Population figures used in this report were obtained from the U.S. Bureau of the Census (see Appendix C).⁷

In conformity with the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program guidelines, the incidence rates excluded the following:

- in-situ cases, except bladder;
- basal and squamous cell skin cancers;
- cases with unknown age; and
- cases with unknown gender.

Of the total number of invasive and in-situ cases for 2000 (5,756), a total of 5,338 cases (5,223 invasive and 115 bladder in-situ) were used for calculating ageadjusted incidence rates. Of the 5,338 cases, 2,838 occurred among males and 2,499 occurred among females.

Age-specific Incidence Rates

Age-specific rates are calculated by dividing the number of cases for a given age-group by the total population of that age group and are expressed as an average annual rate per 100,000 population by age group. Age-specific rates exclude the same types of cases that are excluded from age-adjusted incidence rates.

Observed vs. Expected Numbers of Cases

The expected numbers of cases were calculated using the indirect method of ageadjustment. For each health district, the expected numbers of cases were calculated using rates for the remainder of Idaho. The observed and expected numbers exclude in-situ cases (except bladder), basal and squamous cell skin cancers, and cases with unknown age or sex. Statistically significant differences between observed and expected cases (standardized incidence ratios) were marked (+) for p 0.05 and (*) for p 0.01. Statistical significance does not necessarily imply that concern is warranted, since differences can occur as a result of multiple factors.

Risk and Associated Factors

The "risk and associated factors" subsections in Section I were developed from extracts of the 1993 annual report

of the Washington State Cancer Registry, the "American Cancer Society Textbook of Clinical Oncology," and the U.S. Department of Health and Human Services 9th Report on Carcinogens. 8-10 Socio-economic status is abbreviated as SES in Section I text.

Mean/Median/Mode

Measures of central tendency are helpful to describe a group of individual values in a simple and concise manner.

Mean also known as the arithmetic average, is the sum of all observations divided by the number of observations.

<u>Median</u> is the middle value when the observations are ranked in order from the smallest to the largest.

<u>Mode</u> is the value which occurs most frequently in a group of observed values.

Confidence Intervals

An estimated range of values within which the true population value lies with given probability is the confidence interval.

Cancer Case Definition

A "cancer case" is defined as a primary cancer site (where the cancer started), not a metastatic cancer site (where the cancer spread to). Since an individual can have more than one primary cancer site during their lifetime, the number of incident cancer cases is greater than the number of persons who are diagnosed with cancer.

Limitations to Data Interpretation and Comparison

Rates based on population estimates: In

non-census years, state and county population figures are estimates. Errors in the estimates will impact the rates.

Rate comparisons: Age-adjusted incidence rates and age-specific rates based on small numbers of cases (fewer than 10 cases) may be unstable. In comparing rates among geographic areas (counties, health districts, or states), factors such as the absolute numbers of cases and differences in demographics should be considered. Interpretations without consideration of these factors may be misleading or inaccurate.

Racial misclassification: Many source documents used to report cancer do not specify race of the patient, or misclassify race. Studies have shown racial misclassification rates of nearly 50% for Native Americans. This can result in substantial bias, and is the reason why race-specific rates are not published in this report.

Standard Site Analyses Categories

To facilitate interpretation of data and comparisons across registries, CDRI uses standardized groupings of site analysis categories. These groupings are consistent with the National Cancer Institute's SEER Program and are adopted by NAACCR. 4,5 Most neoplasms are grouped by the organ where they occur. Neoplasms of the lymphatic, hematopoietic, and reticuloendothelial systems are grouped by their histologies (leukemias, lymphomas, etc.), and not by the anatomic site where they occurred. Melanoma of the skin is a combination of both anatomic site and histologic type. See Appendix A for groupings of codes. SEER rates for Section 1 were calculated using SEER*Stat. 11

Stage at Time of Diagnosis

Staging measures the extent of disease at the time of initial diagnosis. Summary staging attempts to group cases with similar prognoses into categories of:

- in-situ (non-invasive),
- localized (cancer confined to the primary site),
- regional (direct extensive of tumor to adjacent organs, and/or lymph nodes),
- distant (metastasis to tissues or lymph nodes remote from the primary site), or
- unknown.

Risks of Developing and Dying from Cancer

Cancer incidence and mortality risks were estimated using DEVCAN Version 4.1 software.¹² DEVCAN was used to calculate the probability of developing or dying of cancer using Idaho-specific cancer incidence and mortality data for the years 1996-2000. The estimates generated are similar to estimates derived using incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, mortality data from the National Center for Health Statistics, and population estimates from census data. DEVCAN was developed by Information Management Services, Inc. in consultation with the Applied Research Branch of the National Cancer Institute. DEVCAN uses a standard multiple decrement life table.

Page 8

SECTION I


2000 SUMMARY ON ALL SITES COMBINED AND 24 MOST COMMON SITES

ALL SITES

Incidence and Mor	rtality S	ummar	у
Age-adjusted incidence	Total 449.0	Male 523.9	Female 394.1
rate per 100,000			
# of new invasive cases # of new in-situ cases	5,223 533	2,749 229	2,473 304
# of deaths	2.131	1,128	1.003

Total Cases By County						
Ada	1,273	Cassia	74	Lewis	38	
Adams	19	Clark	1	Lincoln	23	
Bannock	256	Clearwater	40	Madison	51	
Bear Lake	26	Custer	23	Minidoka	76	
Benewah	51	Elmore	100	Nez Perce	234	
Bingham	130	Franklin	34	Oneida	14	
Blaine	65	Fremont	48	Owyhee	34	
Boise	22	Gem	86	Payette	89	
Bonner	173	Gooding	68	Power	23	
Bonneville	326	Idaho	66	Shoshone	90	
Boundary	45	Jefferson	66	Teton	18	
Butte	13	Jerome	81	Twin Falls	352	
Camas	7	Kootenai	658	Valley	55	
Canyon	515	Latah	118	Washington	73	
Caribou	29	Lemhi	43			

Stage at Diagnosis - All Sites



Risk and Associated Factors

Age Rates usually increase steadily with age. Most cases are adults in mid-life or older.

Gender Males have a higher incidence than females for most cancer types.

Race & SES Rates are higher for African Americans than for Caucasians and other ethnic groups. Rates

are generally higher among lower income groups.

Occupation Risk for cancer is greater with some kinds of workplace exposures, such as some chemi-

cals, asbestos, and radiation.


Diet Diets that are low in fresh fruits and vegetables have been associated with increased inci-


dence of several cancers.

Other Tobacco use is the single most important risk factor for cancer incidence and mortality.

Special Notes	
Mean age-adjusted incidence rate across health districts:	431.4
95% confidence interval on the mean age-adjusted incidence rate:	397.8 - 465.0
Median age-adjusted incidence rate of health districts:	423.7
Range of age-adjusted incidence rate for health districts:	362.5 - 494.0
SEER rate (1998, Whites):	462.5

The incidence rates for all cancers combined were similar for males and females in Idaho until approximately age 60-64, after which rates for males rose dramatically. The highest rates for both males and females were observed in age groups after age 70, peaking in the age group 80-84 for both males and females. Health Districts 1 (p<0.01) and 4 (p<0.01) had statistically significantly more cases of cancer than expected based upon rates for the remainder of Idaho, and Health Districts 3 (p<0.05), 6 (p<0.01) and 7 (p<0.05) had statistically significantly fewer cases than expected.






BLADDER

Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	22.1	39.4	8.3				
# of new invasive cases	145	117	28				
# of new in-situ cases	115	89	26				
# of deaths	53	37	16				

Total Cases By County

Ada	59	Cassia	2	Lewis	4
Adams	2	Clark	1	Lincoln	2
Bannock	9	Clearwater	2	Madison	2
Bear Lake	2	Custer	2	Minidoka	-
Benewah	4	Elmore	3	Nez Perce	18
Bingham	7	Franklin	3	Oneida	1
Blaine	4	Fremont	2	Owyhee	2
Boise	1	Gem	-	Payette	5
Bonner	6	Gooding	4	Power	2
Bonneville	12	Idaho	3	Shoshone	4
Boundary	-	Jefferson	3	Teton	1
Butte	-	Jerome	1	Twin Falls	15
Camas	2	Kootenai	38	Valley	1
Canyon	21	Latah	4	Washington	3
Caribou	-	Lemhi	2		

Stage at Diagnosis - Bladder



Risk and Associated Factors

Age Rates usually increase steadily with age.

Gender Males have substantially higher rates than females.

Race Incidence rates are slightly higher in African Americans.

Occupation Occupational exposures, most prominently aniline dye used in textile, rubber, and cable industries, are associated with a large proportion of cases. Exposure to permanent hair

industries, are associated with a large proportion of cases. Exposure to permanent hair dyes increases risk.

uyes increases risk.

Other Tobacco consumption has been associated with a six-fold higher incidence of bladder tumor.

Cyclophosphamide, a chemotherapeutic agent, and 4-amino-diphenyl are known human bladder carcinogens. Beta-naphthylamine and tobacco tar have been implicated in animal studies as possible causative factors. Chronic infections, calculus disease, and


Schistosoma hematobium may also cause bladder tumors. Nitrate in drinking water, one of the most common contaminants in rural areas, is associated with an increased risk for blad-


der cancer.

Special Notes

Mean age-adjusted incidence rate across health districts:	21.9
95% confidence interval on the mean age-adjusted incidence rate:	18.4 - 25.5
Median age-adjusted incidence rate of health districts:	19.7
Range of age-adjusted incidence rate for health districts:	17.5 - 28.4
SEER rate (1998, Whites):	21.6

There were few cases of bladder cancer among persons aged less than 40 years. Bladder cancer incidence rates increased with age, peaking in the age group 85+ for males, and 70-74 for females. Health District 1 had statistically significantly more cases than expected based upon rates for the remainder of Idaho (p<0.05).






BRAIN

Incidence and Mortality Summary						
	Total	Male	Female			
Age-adjusted incidence rate per 100,000	7.1	8.8	5.3			
# of new invasive cases	86	52	34			
# of new in-situ cases	0	0	0			
# of deaths	66	39	27			



Ada	23	Cassia	1	Lewis	1
Adams	-	Clark	-	Lincoln	
Bannock	5	Clearwater	1	Madison	
Bear Lake	-	Custer	-	Minidoka	
Benewah	-	Elmore	-	Nez Perce	2
Bingham	2	Franklin	-	Oneida	
Blaine	2	Fremont	-	Owyhee	1
Boise	-	Gem	2	Payette	4
Bonner	3	Gooding	-	Power	
Bonneville	5	Idaho	2	Shoshone	3
Boundary	-	Jefferson	5	Teton	2
Butte	-	Jerome	-	Twin Falls	6
Camas	-	Kootenai	7	Valley	1
Canyon	3	Latah	2	Washington	1
Caribou	1	Lemhi	-		

Stage at Diagnosis - Brain



Risk and Associated Factors

Age This is the second most common cancer among children, following leukemia. Adult malignant brain tumors are most common after age 60.

Gender Males have higher rates than females.

Race & SES The incidence rate is higher in Caucasians and higher social classes.

Genetics Certain genetic factors may cause an increased risk of some malignant brain tumors, includ-

ing gliomas. Molecular tests that may be useful in screening for recurrences are being

developed.

Occupation Vinyl chloride is a known human carcinogen, with exposure causing brain cancer and other

types of cancer. Many occupational and environmental exposures have shown suggestive associations with elevated rates of brain cancer, including radiation, and agricultural chemicals. Roofers, sheet metal workers, and rubber and plastic workers may be at elevated risk.

Studies about these associations are still inconclusive.


Other Human Immunodeficiency Virus (HIV) infected individuals have an increased risk of devel-


oping brain lymphoma.

Special Notes

Mean age-adjusted incidence rate across health districts:	6.9
95% confidence interval on the mean age-adjusted incidence rate:	6.1 - 7.8
Median age-adjusted incidence rate of health districts:	7.2
Range of age-adjusted incidence rate for health districts:	5.6 - 8.3
SEER rate (1998, Whites):	6.5

The age-related incidence of brain cancer is typically bimodal, usually with a peak in infancy and childhood, a gradual rise in young adulthood, and a broader, sustained peak during the fifth to eighth decade of life. This trend is difficult to discern in Idaho's population due to the relatively small number of cases observed annually, which increases the variability in age-specific rates. No health districts had statistically significantly more, or fewer, cases than expected based upon rates for the remainder of Idaho.






BREAST

Incidence and Mortality Summary					
Age-adjusted incidence rate per 100,000	Total	Male	Female		
	69.7	1.4	131.6		
# of new invasive cases	834	8	826		
# of new in-situ cases	149		148		
# of deaths	179	1	178		





Total Cases By County

Ada	247	Cassia	13	Lewis	6
Adams	2	Clark	-	Lincoln	3
Bannock	49	Clearwater	9	Madison	12
Bear Lake	3	Custer	2	Minidoka	12
Benewah	3	Elmore	12	Nez Perce	38
Bingham	25	Franklin	5	Oneida	1
Blaine	18	Fremont	11	Owyhee	7
Boise	5	Gem	17	Payette	11
Bonner	33	Gooding	8	Power	3
Bonneville	62	Idaho	13	Shoshone	16
Boundary	10	Jefferson	8	Teton	-
Butte	3	Jerome	14	Twin Falls	63
Camas	1	Kootenai	98	Valley	7
Canyon	84	Latah	21	Washington	15
Caribou	3	Lemhi	5		

Risk and Associated Factors

Age Rates increase steadily with age. Age is the single most important risk factor for breast cancer. A 60-year old white American woman's risk of developing breast cancer is fourteen

times that of a 30-year old American woman.

Race & SES Genetics Hormonal

Other

Caucasians have higher incidence rates as do women in higher income groups.

Specific genes associated with breast cancers have been identified and are being studied. There is evidence of hormonal influence in the risk of developing breast cancer. Longer intervals of menarche to the first full-term pregnancy and menarche to menopause, as well

as menarche before age 13, have been associated with higher risks of breast cancer. High dietary fat intake, obesity, sedentary life-style, and having a mother or sister with


breast cancer have all been implicated as associated risk factors. Epstein-Barr virus may


increase the risk of metastasis.

Special Notes

Mean age-adjusted incidence rate across health districts:	128.8
95% confidence interval on the mean age-adjusted incidence rate:	120.4 - 137.2
Median age-adjusted incidence rate of health districts:	126.6
Range of age-adjusted incidence rate for health districts:	116.1 - 146.8
SEER rate (1998, Whites):	140.8

The vast majority of breast cancer cases occur among females. In Idaho during the year 2000, there were eight cases of invasive breast cancer among males. The age-specific incidence rates of female breast cancer in Idaho in 2000 increased with age, peaking in the age group 80-84. No cases were observed in women less than 25 years of age. Health District 4 had statistically significantly more cases of female breast cancer than expected based upon rates for the remainder of Idaho (p<0.05).






CERVIX

Incidence and Mortality Summary					
	Total	Male	Female		
Age-adjusted incidence rate per 100,000	-	-	6.4		
# of new invasive cases	-	-	39		
# of new in-situ cases	-	-	n/a		
# of deaths	-	-	10		

Total Cases By County

Ada	7	Cassia	-	Lewis	1
Adams	-	Clark	-	Lincoln	
Bannock	2	Clearwater	1	Madison	
Bear Lake	-	Custer	-	Minidoka	1
Benewah	-	Elmore	2	Nez Perce	1
Bingham	-	Franklin	-	Oneida	-
Blaine	-	Fremont	-	Owyhee	1
Boise	-	Gem	-	Payette	-
Bonner	1	Gooding	4	Power	-
Bonneville	3	Idaho	1	Shoshone	-
Boundary	-	Jefferson	-	Teton	-
Butte	-	Jerome	1	Twin Falls	2
Camas	-	Kootenai	5	Valley	1
Canyon	4	Latah	1	Washington	-
Caribou	-	Lemhi	-		

Stage at Diagnosis - Cervix



Risk and Associated Factors

Cervical cancer occurs in adult women of any age. However, the majority of invasive cases Age are diagnosed in older women.


Race & SES African American females, as well as women in lower income groups, have been shown to experience higher rates.


Other Strong risk factors for cervical cancer and its precursors include: early age at first inter-

course (less than 16 years old), a history of multiple sexual partners, a large number of pregnancies, a history of genital human papilloma virus infection or other sexually transmitted disease, and the presence of other genital tract neoplasia. Exposure to cigarette smoke is also a known risk factor, although by unknown mechanisms. Diethylstilbestrol use during pregnancy increased clear-cell adenocarcinoma in daughters exposed in utero.

Special Notes	
Mean age-adjusted incidence rate across health districts:	6.6
95% confidence interval on the mean age-adjusted incidence rate:	4.5 - 8.7
Median age-adjusted incidence rate of health districts:	6.2
Range of age-adjusted incidence rate for health districts:	2.8 - 10.4
SEER rate (1998, Whites):	9.0

No cases of invasive cervical cancer were diagnosed in females less than 30 years of age. Increased screening with routine Pap tests, particularly among older and low-income women, has increased diagnostic rates and helped to reduce the incidence of invasive disease. Today, the vast majority of cases in younger women is diagnosed before the invasive stage, with cure rates approaching 100%. These pre-invasive cases are not included in this report. No health district had statistically significantly more, or fewer, cases than expected based upon rates for the remainder of Idaho.






COLON (excluding rectum)

Incidence and Mortality Summary					
	Total	Male	Female		
Age-adjusted incidence rate per 100,000	33.2	33.9	32.7		
# of new invasive cases	390	178	212		
# of new in-situ cases	14	5	9		
# of deaths	157	73	84		

Total Cases By County

Ada	76	Cassia	6	Lewis	6
Adams	4	Clark	-	Lincoln	1
Bannock	18	Clearwater	3	Madison	5
Bear Lake	6	Custer	3	Minidoka	7
Benewah	6	Elmore	6	Nez Perce	23
Bingham	10	Franklin	2	Oneida	1
Blaine	6	Fremont	2	Owyhee	-
Boise	1	Gem	7	Payette	6
Bonner	14	Gooding	8	Power	2
Bonneville	22	Idaho	3	Shoshone	9
Boundary	3	Jefferson	6	Teton	2
Butte	1	Jerome	2	Twin Falls	18
Camas	1	Kootenai	40	Valley	2
Canyon	42	Latah	9	Washington	5
Caribou	4	Lemhi	2		

Stage at Diagnosis - Colon



Risk and Associated Factors

Age Rates increase with age; the vast majority of cases occur after age 50.

Gender Genetics Incidence rates are slightly higher in males.

Specific genetic alterations have been recognized in several hereditary conditions with high risk of colon cancer, such as familial polyposis. These conditions account for about six percent of colon cancer cases.

Diet


Strong evidence that diets high in fat and low in fiber contribute to increased risk of colon cancer has been shown.


Other

Individuals with a close family history of this cancer and those with a personal history of certain other cancers are at increased risk. Regular, moderate physical activity is associated with lower rates of this cancer.

Special Notes	
Mean age-adjusted incidence rate across health districts:	33.1
95% confidence interval on the mean age-adjusted incidence rate:	30.0 - 36.1
Median age-adjusted incidence rate of health districts:	32.4
Range of age-adjusted incidence rate for health districts:	26.4 - 38.6
SEER rate (1998, Whites):	38.5

No cases of colon cancer were diagnosed in persons less than 35 years of age. There was a steep increase in age-specific incidence rates starting at age 55 and peaking in the age group 75-79 for females and 80-84 for males. No health district had statistically significantly more, or fewer, cases than expected based upon rates for the remainder of Idaho.






ENDOMETRIUM

Incidence and Mortality Summary					
	Total	Male	Female		
Age-adjusted incidence rate per 100,000	-	-	21.7		
# of new invasive cases	-	-	137		
# of new in-situ cases	-	-	4		
# of deaths	-	-	13		

Total Cases By County

Ada	30	Cassia	2	Lewis	-
Adams	1	Clark	-	Lincoln	-
Bannock	3	Clearwater	2	Madison	1
Bear Lake	2	Custer	-	Minidoka	1
Benewah	1	Elmore	1	Nez Perce	5
Bingham	2	Franklin	2	Oneida	-
Blaine	2	Fremont	4	Owyhee	2
Boise	1	Gem	4	Payette	1
Bonner	2	Gooding	2	Power	-
Bonneville	7	Idaho	1	Shoshone	2
Boundary	1	Jefferson	-	Teton	-
Butte	1	Jerome	1	Twin Falls	9
Camas	-	Kootenai	21	Valley	4
Canyon	15	Latah	3	Washington	1
Caribou	1	Lemhi	1		

Stage at Diagnosis - Endometrium



Risk and Associated Factors

Age Occurs predominantly after menopause, with median age 58 and peaking at the 50 to 60 age group.

Race & SES Caucasian women have higher rates than African American women.

Genetics Familial tendency has been observed.

Diet Dietary fat may play a role in increased risk. Obesity and hypertension are common associ-


ated conditions of endometrial cancer.


Hormonal Factors that elevate levels of estrogen or decrease progesterone levels enhance the risk.

Women who have never carried a pregnancy to term are at a relatively high risk. Risk decreases as the number of pregnancies increases. An increased incidence of endometrial cancer has been found in association with prolonged, unopposed estrogen exposure as well as with tamoxifen treatment of breast cancer.

Special Notes	
Mean age-adjusted incidence rate across health districts:	21.1
95% confidence interval on the mean age-adjusted incidence rate:	18.5 - 23.7
Median age-adjusted incidence rate of health districts:	21.2
Range of age-adjusted incidence rate for health districts:	15.7 - 26.6
SEER rate (1998, Whites):	25.4

No cases of endometrial cancer were diagnosed in persons less than 40 years of age. There was a sharp increase in age-specific rates, peaking in the age group 80-84. No health district had statistically significantly more, or fewer, cases than expected based upon rates for the remainder of Idaho.






ESOPHAGUS

Incidence and Mor	tality S	ummar	y
	Total	Male	Female
Age-adjusted incidence rate per 100,000	5.8	9.2	2.8
# of new invasive cases	69	51	18
# of new in-situ cases	4	3	1
# of deaths	47	34	13

Total Cases By County

Ada	10	Cassia	2	Lewis	
Adams	-	Clark	-	Lincoln	
Bannock	4	Clearwater	1	Madison	
Bear Lake	-	Custer	-	Minidoka	1
Benewah	2	Elmore	1	Nez Perce	2
Bingham	1	Franklin	-	Oneida	
Blaine	1	Fremont	3	Owyhee	1
Boise	1	Gem	3	Payette	1
Bonner	2	Gooding	-	Power	1
Bonneville	2	Idaho	1	Shoshone	1
Boundary	-	Jefferson	-	Teton	
Butte	1	Jerome	1	Twin Falls	3
Camas	-	Kootenai	8	Valley	4
Canyon	9	Latah	2	Washington	1
Caribou	-	Lemhi	1		

Stage at Diagnosis - Esophagus



Risk and Associated Factors


Age Gender Race & SES Occupation Other Incidence of esophageal cancer is highest after age 55.


It is predominantly a disease of the male, with male-to-female ratios of about 3:1 or more. United States data show that African Americans are affected more than Caucasians. Chimney sweeps exposed to soot are at higher risk.

Tobacco use (cigarettes or spit tobacco) and heavy alcohol consumption are major risk factors for cancer of the esophagus. The risk is particularly increased when these two factors are both present.

Special Notes	
Mean age-adjusted incidence rate across health districts:	5.6
95% confidence interval on the mean age-adjusted incidence rate:	4.7 - 6.5
Median age-adjusted incidence rate of health districts:	5.1
Range of age-adjusted incidence rate for health districts:	4.6 - 7.7
SEER rate (1998, Whites):	4.3

No cases of esophageal cancer were diagnosed in person less than 35 years of age. The age-specific incidence rates peaked in the age group 75-79 for both males and females. No health district had statistically significantly more, or fewer, cases than expected based upon rates for the remainder of Idaho.






HODGKIN'S LYMPHOMA

Incidence and Mor	tality S	ummar	y
	Total	Male	Female
Age-adjusted incidence rate per 100,000	2.2	3.2	1.3
# of new invasive cases	28	20	8
# of new in-situ cases	0	0	0
# of deaths	6	2	4

Stage at Diagnosis - Hodgkins Lymphoma



Total Cases By County

Ada	8	Cassia	-	Lewis	
Adams	-	Clark	-	Lincoln	
Bannock	-	Clearwater	-	Madison	
Bear Lake	-	Custer	-	Minidoka	
Benewah	-	Elmore	1	Nez Perce	1
Bingham	-	Franklin	-	Oneida	
Blaine	-	Fremont	-	Owyhee	
Boise	-	Gem	1	Payette	
Bonner	2	Gooding	1	Power	
Bonneville	3	Idaho	-	Shoshone	
Boundary	-	Jefferson	1	Teton	
Butte	-	Jerome	1	Twin Falls	2
Camas	-	Kootenai	5	Valley	1
Canyon	1	Latah	-	Washington	
Caribou	-	Lemhi	-		

Risk and Associated Factors

Age High rates are seen in young adults and in later age groups especially among males.

Gender Males have higher rates than females.

Race & SES There is a lower incidence among African Americans. Hodgkin's lymphoma is more com-

mon in higher income groups.

Genetics Genetic factors are thought to play an important role in the etiology of Hodgkin's lymphoma,

but these are yet to be adequately defined.


Other Certain viral infections are thought to also increase risk but no clear association has been


established. With current treatment, Hodgkin's disease, which was once highly fatal, is

among the most curable of all cancers.

Special Notes Mean age-adjusted incidence rate across health districts: 95% confidence interval on the mean age-adjusted incidence rate: Median age-adjusted incidence rate of health districts: Range of age-adjusted incidence rate for health districts: SEER rate (1998, Whites): 3.0

The age-related incidence of Hodgkin's lymphoma is typically bimodal, usually with a peak in the late 20s to early 30s, and another peak in the ninth decade of life. This trend is difficult to discern in Idaho's population due to the relatively small number of cases observed annually, which increases the variability in age-specific rates. Health District 1 had statistically significantly more cases than expected based upon rates for the remainder of Idaho (p<0.05).






KIDNEY

Incidence and Mor	tality S	ummar	у
	Total	Male	Female
Age-adjusted incidence rate per 100,000	11.2	14.0	8.9
# of new invasive cases	134	78	56
# of new in-situ cases	3	2	1
# of deaths	46	24	22

Total Cases By County

Ada	31	Cassia	2	Lewis	1
Adams	1	Clark	-	Lincoln	1
Bannock	5	Clearwater	3	Madison	2
Bear Lake	-	Custer	1	Minidoka	4
Benewah	1	Elmore	4	Nez Perce	7
Bingham	5	Franklin	-	Oneida	1
Blaine	1	Fremont	-	Owyhee	-
Boise	1	Gem	4	Payette	2
Bonner	4	Gooding	1	Power	-
Bonneville	11	Idaho	1	Shoshone	-
Boundary	1	Jefferson	1	Teton	-
Butte	1	Jerome	3	Twin Falls	5
Camas	-	Kootenai	14	Valley	-
Canyon	14	Latah	1	Washington	-
Caribou	1	Lemhi	-		

Stage at Diagnosis - Kidney



Risk and Associated Factors

Age Both adults and children are at risk for kidney cancer. Renal cell carcinoma accounts for 80% of all adult kidney cancers. Wilm's tumor (nephroblastoma) affects predominantly chil-

dren under age 5 and accounts for the majority of childhood kidney cancers.

Gender Renal cell carcinoma affects males twice as often as females.Genetics Wilm's tumor often occurs with congenital defects.

Occupation Certain occupations, such as laundry and leather workers, have an increased risk due to

chemical exposure.


Other Cigarette smoking is strongly associated with adult kidney cancer. Smokers are at twice the


risk of developing kidney cancer as non-smokers. Analgesic mixtures containing phenacetin

increase the risk of kidney cancer.

Special Notes Mean age-adjusted incidence rate across health districts: 95% confidence interval on the mean age-adjusted incidence rate: 10.0 - 12.2 Median age-adjusted incidence rate of health districts: 11.3 Range of age-adjusted incidence rate for health districts: 9.3 - 13.5 SEER rate (1998, Whites): 11.3

There were no cases of kidney or renal pelvis cancer among persons aged 5-14 years. The highest incidence among males was in the age group 85+. The highest incidence among females was in the age group 75-79. No health district had statistically significantly more, or fewer, cases than expected based upon rates for the remainder of Idaho.






LARYNX

Incidence and Mor	tality S	ummar	y
	Total	Male	Female
Age-adjusted incidence rate per 100,000	3.0	6.0	0.5
# of new invasive cases	35	32	3
# of new in-situ cases	3	2	1
# of deaths	16	15	1

Total Cases By County

Ada	5	Cassia	2	Lewis	1
Adams	-	Clark	-	Lincoln	-
Bannock	3	Clearwater	-	Madison	-
Bear Lake	-	Custer	-	Minidoka	2
Benewah	-	Elmore	2	Nez Perce	5
Bingham	1	Franklin	-	Oneida	1
Blaine	-	Fremont	-	Owyhee	-
Boise	-	Gem	1	Payette	-
Bonner	-	Gooding	-	Power	2
Bonneville	1	Idaho	-	Shoshone	2
Boundary	-	Jefferson	1	Teton	-
Butte	-	Jerome	-	Twin Falls	2
Camas	-	Kootenai	3	Valley	-
Canyon	2	Latah	2	Washington	-
Caribou	-	Lemhi	-		

Stage at Diagnosis - Larynx



Risk and Associated Factors

Age Rates increase with age, with the vast majority of cases occurring after age 55.

Gender Much more common in males than females.

Race & SES Generally in the United States, African Americans have higher incidence rates than

Caucasians. Lower income groups experience higher rates.

Occupation Laryngeal cancer has been associated with exposures such as asbestos and wood dust.


Diet Diets low in fresh fruits and vegetables may increase the risk


Diet Diets low in fresh fruits and vegetables may increase the risk. **Other** Cigarette smoking and alcohol use are both major risk factors.

Cigarette smoking and alcohol use are both major risk factors. The combination of alcohol consumption and tobacco use (smoking or spit tobacco) acts greatly to increase the risk. A patient with a single laryngeal cancer who continues to smoke and drink alcohol has an enhanced risk of developing a second laryngeal tumor.

Special Notes	
Mean age-adjusted incidence rate across health districts:	3.3
95% confidence interval on the mean age-adjusted incidence rate:	1.9 - 4.6
Median age-adjusted incidence rate of health districts:	2.7
Range of age-adjusted incidence rate for health districts:	1.6 - 6.5
SEER rate (1998, Whites):	3.6

There were no cases of laryngeal cancer among persons aged less than 40 years. The age-specific incidence rates for males were more than twice those for females in most age groups. The highest incidence rate among males was in the age group 70-74. The highest incidence rate among females was in the age group 75-79. Health District 2 had statistically significantly more cases than expected based upon rates for the remainder of Idaho (p<0.05).





LEUKEMIA

Ada

Adams

Bannock

Bear Lake

Benewah

Bingham

Blaine

Boise

Butte

Camas

Canyon

Caribou


Bonner

Bonneville


Boundary

Incidence and Mor	tality S	ummar	у
	Total	Male	Female
Age-adjusted incidence rate per 100,000	11.3	14.9	8.5
# of new invasive cases	136	81	55
# of new in-situ cases	0	0	0
# of deaths	90	54	36

Lemhi









Risk and Associated Factors

Age	This is the most common form of cancer in children. Incidence usually increases with age in adults. The highest rates occur in individuals over age 60.
Gender	Males have a higher incidence than females for chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
Race	ALL is less common among African Americans. CLL is rare in Asians.
Genetics	Certain congenital defects such as trisomy 21, Fanconi's anemia, Bloom syndrome, and ataxia-telangectasia, increase risk in children for various types of leukemia.
Occupation	Benzene is a known cause of leukemia (predominantly acute myelogenous leukemia [AML]). Chimney sweeps exposed to soot are at higher risk.
Other	lonizing radiation exposure increases the risk. Environmental exposure to low frequency, non-ionizing radiation and its association with leukemia incidence is being investigated. Treatment with some chemotherapeutic agents for other cancers increases the risk of leukemia.

Special Notes		
Mean age-adjusted incidence rate across health districts:	10.9	
95% confidence interval on the mean age-adjusted incidence rate:	9.3 - 12.6	
Median age-adjusted incidence rate of health districts:	11.3	
Range of age-adjusted incidence rate for health districts:	6.9 - 14.2	
SEER rate (1998, Whites):	11.7	

The age-specific incidence distribution of leukemia for Idaho is quite similar to the typical pattern described by the SEER program of the National Cancer Institute. The rates are higher for males than females for all types of leukemia with the exception of acute myelogenous leukemia (AML), which has no predilection for age or sex. Generally, the incidence of leukemia is higher in older age groups. No health district had statistically significantly fewer or more cases than expected based upon rates for the remainder of Idaho.






LIVER

Incidence and Mortality Summary					
Age-adjusted incidence	Total 2.7	Male 4.0	Female 1 7		
rate per 100,000	2.1	4.0	1.7		
# of new invasive cases	32	22	10		
# of new in-situ cases	0	0	0		
# of deaths	44	34	10		

Total Cases By County

Ada	6	Cassia	-	Lewis	
Adams	-	Clark	-	Lincoln	
Bannock	2	Clearwater	-	Madison	
Bear Lake	-	Custer	-	Minidoka	
Benewah	-	Elmore	-	Nez Perce	2
Bingham	-	Franklin	-	Oneida	
Blaine	-	Fremont	-	Owyhee	
Boise	-	Gem	-	Payette	
Bonner	1	Gooding	-	Power	
Bonneville	2	Idaho	1	Shoshone	
Boundary	1	Jefferson	-	Teton	
Butte	-	Jerome	-	Twin Falls	6
Camas	-	Kootenai	5	Valley	
Canyon	5	Latah	-	Washington	
Caribou	-	Lemhi	1		

Stage at Diagnosis - Liver



Risk and Associated Factors

Age The incidence rate of liver cancer increases with age.

Gender Rates are usually higher in males than in females.

Race Incidence is higher in Asians and African Americans than for the rest of the population.Diet Aflatoxins, which are present in certain foods such as peanut butter, are classified as a

known human carcinogen, causing liver cancer.

Occupation Thorium dioxide exposure increases liver cancer risk. Exposure to vinyl chloride used in

plastic production is associated with an increased risk of angiosarcoma of the liver.


Chimney sweeps exposed to soot are at higher risk.


Other Cigarette smoking increases the risk. Hepatitis B and Hepatitis C infections are significant causes of hepatocellular carcinoma. Cirrhosis of the liver due to viral hepatitis, alcoholism,

or toxic chemical exposure accounts for 50-80% of patients diagnosed with liver cancer.

Special Notes	
Mean age-adjusted incidence rate across health districts:	2.7
95% confidence interval on the mean age-adjusted incidence rate:	2.1 - 3.3
Median age-adjusted incidence rate of health districts:	2.8
Range of age-adjusted incidence rate for health districts:	1.4 - 3.8
SEER rate (1998, Whites):	4.5

There were few cases of liver cancer among persons less than 50 years of age. Age-specific incidence rates increased with age, peaking in the age group 75-79 for males and 65-69 for females. No health district had statistically significantly fewer or more cases than expected based upon rates for the remainder of Idaho.






LUNG

Caribou


Incidence and Mortality Summary					
	Total	Male	Female		
Age-adjusted incidence rate per 100,000	58.9	78.5	43.3		
# of new invasive cases	692	418	274		
# of new in-situ cases	0	0	0		
# of deaths	538	316	222		



Lemhi

5 Bannock 18 Clearwater 2 Madison 7 8 Bear Lake Custer 3 Minidoka Benewah 9 Elmore Nez Perce 19 42 Bingham 13 Franklin Oneida 3 Blaine Fremont 5 Owyhee 6 Boise 3 Gem 12 Payette 21 Bonner 21 Gooding 5 Power 2 Bonneville Idaho Shoshone 18 Boundary Jefferson 8 3 6 Teton Butte Jerome 11 Twin Falls 49 Camas Kootenai 86 Valley 8 Canyon 55 Latah 12 Washington 18

Stage at Diagnosis - Lung and Bronchus



Risk and Associated Factors

5

Age Lung cancer incidence rates increase with age.

Gender The incidence is currently higher in males than in females, but the gap is narrowing due to

increased smoking rates in women.

Race & SES Generally, incidence is higher among African Americans than other racial groups and is also

higher in lower income groups.

Diet Diets low in consumption of fresh fruits and vegetables contribute to increased risk.

Occupation Occupational or environmental exposures to asbestos, cadmium, chromium, coal tars, crys-

talline silica dust, polycyclic aromatic hydrocarbons, radon, soot, and other substances


increase the risk.


Other Cigarette smoking, including exposure to second-hand smoke, is the most important risk

factor, accounting for over 85% of lung cancer deaths.

Special Notes				
Mean age-adjusted incidence rate across health districts:	56.5			
95% confidence interval on the mean age-adjusted incidence rate: Median age-adjusted incidence rate of health districts:	45.3 - 67.7 61.6			
Range of age-adjusted incidence rate for health districts: SEER rate (1998, Whites):	29.9 - 74.1 61.7			

There were few cases of lung cancer among persons less than 50 years of age. The age-specific incidence rates for males were uniformly higher than the rates for females after age 65. The incidence rates increased with age, peaking in the age group 80-84 for males, and 75-79 for females. Health Districts 1 and 4 (p<0.01) had statistically significantly more cases than expected based upon rates for the remainder of ldaho. Health Districts 6 (p<0.01) and 7 (p<0.05) had statistically significantly fewer cases than expected based upon rates for the remainder of ldaho.






MELANOMA

Incidence and Mortality Summary					
	Total	Male	Female		
Age-adjusted incidence rate per 100,000	19.4	24.5	15.0		
# of new invasive cases	234	139	94		
# of new in-situ cases	199	113	86		
# of deaths	37	22	15		

Total Cases By County

Ada	90	Cassia	2	Lewis	-
Adams	2	Clark	-	Lincoln	1
Bannock	17	Clearwater	2	Madison	1
Bear Lake	1	Custer	-	Minidoka	4
Benewah	7	Elmore	9	Nez Perce	14
Bingham	5	Franklin	2	Oneida	1
Blaine	1	Fremont	3	Owyhee	3
Boise	2	Gem	8	Payette	4
Bonner	16	Gooding	4	Power	2
Bonneville	20	Idaho	4	Shoshone	8
Boundary	1	Jefferson	2	Teton	2
Butte	-	Jerome	10	Twin Falls	21
Camas	-	Kootenai	79	Valley	2
Canyon	40	Latah	6	Washington	-
Caribou	-	Lemhi	-		

Stage at Diagnosis - Melanoma of Skin



Risk and Associated Factors

Age Melanoma is extremely uncommon before puberty. Rates increase with age.

Gender It occurs more frequently in males than females.

Race & SES The incidence rate is highest in Caucasians and is uncommon in African Americans. It has

an increased incidence in higher income groups.

Occupation Persons working in occupations associated with increased sun exposure have a higher inci-

dence.


Other Ultra-violet light exposure, especially blistering sunburns during childhood, is a major risk


factor. Melanoma has been on the increase nationally for several decades. People with

light skin and individuals with numerous or atypical moles are at increased risk.

		,
Special Notes		
Mean age-adjusted incidence rate across health districts:	17.2	
95% confidence interval on the mean age-adjusted incidence rate:	13.7 - 20.7	
Median age-adjusted incidence rate of health districts:	15.8	
Range of age-adjusted incidence rate for health districts:	11.5 - 25.4	
SEER rate (1998, Whites):	18.0	


There were few cases of melanoma of the skin among persons less than 25 years of age. The age-specific incidence rates were higher among males after age 50. Health District 1 (p<0.05) and had statistically significantly more cases than expected, and Health District 7 (p<0.05) had statistically significantly fewer cases than expected based upon rates for the remainder of Idaho.






MYELOMA

Incidence and Mortality Summary					
	Total	Male	Female		
Age-adjusted incidence rate per 100,000	4.7	6.4	3.6		
# of new invasive cases	56	33	23		
# of new in-situ cases	0	0	0		
# of deaths	41	27	14		







Risk and Associated Factors

Multiple myeloma is an age-dependent cancer. It increases with age and rarely occurs Age before age 40.

Gender Rates for males and females are usually similar. Race

Genetics

African Americans have a higher incidence rate, sometimes twice the rate for Caucasians. Genetic factors play an important role in its development but how so is not completely understood. Familial factors and chronic antigenic stimulation have also been implicated.


Other Multiple myeloma has been associated with lymphomas such as Burkitt's, and non-


Hodgkin's lymphomas. Studies have suggested several possible viral etiologies, and multiple myeloma has been linked to radiation exposures of nuclear workers. Specific environmental exposures such as herbicides and radiation may also play an important role in the

incidence	of	multiple	myeloma.

Special Notes				
Mean age-adjusted incidence rate across health districts:	4.3			
95% confidence interval on the mean age-adjusted incidence rate:	3.3 - 5.4			
Median age-adjusted incidence rate of health districts:	3.8			
Range of age-adjusted incidence rate for health districts:	3.0 - 6.7			
SEER rate (1998, Whites):	4.8			

There were no cases of plasma cell tumors among persons less than 45 years of age. The age-specific incidence rates increased rapidly for both males and females after age group 65-69. Health District 4 (p<0.05) had statistically significantly more cases than expected based upon rates for the remainder of Idaho.







NON-HODGKIN'S LYMPHOMA

tality S	ummar	У
Total	Male	Female
19.4	21.5	17.7
231	118	113
0	0	0
	Total 19.4	19.4 21.5

State at Diagnosis - Non-Hodgkins Lymphoma





Risk and Associated Factors

Rates increase with age reaching the highest levels in the eight and ninth decades of life. Age Gender Males have higher rates than females. Race & SES

Generally in the United States incidence rates are slightly lower in African Americans.

Rates are higher in upper income groups.

Occupation Ethylene oxide exposure at plants producing sterilized medical supplies and spices is a risk

factor.


Other Non-Hodgkin's lymphoma (NHL) develops with increased frequency in individuals infected with certain viruses, particularly the human immunodeficiency virus (HIV), which causes


acquired immunodeficiency syndrome (AIDS). Exposures to agricultural chemicals and high-dose radiation exposures have also been implicated. Treatment with some immunosuppressants increases the risk of NHL among organ transplant patients. Epstein-Barr virus

may increase the risk of metastasis.

Special Notes	
Mean age-adjusted incidence rate across health districts:	18.9
95% confidence interval on the mean age-adjusted incidence rate:	16.3 - 21.4
Median age-adjusted incidence rate of health districts:	18.9
Range of age-adjusted incidence rate for health districts:	13.4 - 22.6
SEER rate (1998, Whites):	19.0

The age-specific incidence rates of non-Hodgkin's lymphoma increased with age, peaking in the age group 85+ for males and females. No health districts had statistically significantly more or fewer cases than expected based upon rates for the remainder of Idaho.






ORAL CAVITY AND PHARYNX

Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	12.4	18.2	7.5				
# of new invasive cases	147	99	48				
# of new in-situ cases	6	5	1				
# of deaths	38	22	16				

Total	Cases	Ву	County

Ada	24	Cassia	2	Lewis	-
Adams	2	Clark	-	Lincoln	2
Bannock	4	Clearwater	-	Madison	-
Bear Lake	1	Custer	1	Minidoka	3
Benewah	4	Elmore	4	Nez Perce	2
Bingham	8	Franklin	1	Oneida	-
Blaine	3	Fremont	4	Owyhee	-
Boise	-	Gem	2	Payette	3
Bonner	6	Gooding	2	Power	-
Bonneville	3	Idaho	1	Shoshone	1
Boundary	3	Jefferson	1	Teton	1
Butte	2	Jerome	3	Twin Falls	16
Camas	-	Kootenai	15	Valley	1
Canyon	8	Latah	-	Washington	2
Caribou	4	Lemhi	-		

Stage at Diagnosis - Oral Cavity



Risk and Associated Factors

Age Most cases occur in people over age 60.

Gender Males have a higher incidence than females.

Race & SES Rates are higher for African Americans than for Caucasians. Rates are also higher among

lower income groups.

Diet Increased risk is associated with diets low in fresh fruit and vegetable consumption.

Occupation Increased risk with textile and leather manufacturing industries.


Other Smoking and spit tobacco are major risk factors for cancers of the oral cavity and pharynx.


Over 90% of cases are associated with tobacco use. Alcohol use, especially excessive, is a major risk factor. Combined exposure to tobacco and alcohol results in substantially higher

risk.

Special Notes Mean age-adjusted incidence rate across health districts: 95% confidence interval on the mean age-adjusted incidence rate: 7.3 - 14.6 Median age-adjusted incidence rate of health districts: 10.5 Range of age-adjusted incidence rate for health districts: 3.0 - 17.9 SEER rate (1998, Whites): 10.5

There were few cases among persons less than 40 years of age. The age-specific incidence rates generally increased with age after age 50, peaking in the age group 85+ for males and females. Health District 5 had statistically significantly more cases than expected (p<0.05), and Health District 2 had statistically significantly fewer cases than expected based upon rates for the remainder of Idaho (p<0.01).






OVARY

Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	-	-	15.6				
# of new invasive cases	-	-	98				
# of new in-situ cases	-	-	0				
# of deaths	-	-	65				

Total Cases By County

Ada	24	Cassia	2	Lewis	1
Adams	-	Clark	-	Lincoln	
Bannock	11	Clearwater	-	Madison	2
Bear Lake	-	Custer	-	Minidoka	
Benewah	-	Elmore	1	Nez Perce	2
Bingham	5	Franklin	2	Oneida	1
Blaine	-	Fremont	1	Owyhee	1
Boise	-	Gem	3	Payette	1
Bonner	4	Gooding	1	Power	
Bonneville	5	Idaho	2	Shoshone	1
Boundary	-	Jefferson	2	Teton	
Butte	-	Jerome	2	Twin Falls	4
Camas	-	Kootenai	4	Valley	
Canyon	11	Latah	1	Washington	3
Caribou	1	Lemhi	-		

Stage at Diagnosis - Ovary



Risk and Associated Factors

Age The rate of ovarian cancer increases with age and it is primarily a disease of older women.

Race & SES Rates are slightly higher in Caucasian females than in African American females. The rate

is higher among upper income groups.

Genetics The most important risk factor for ovarian cancer is a family history of a first-degree relative (mother, daughter, or sister) with the disease. The risk is higher still in women with two or

more first-degree relatives with ovarian cancer.

Hormonal Risk of ovarian cancer is significantly reduced among women having at least one live-born


child, a history of breast-feeding, or sustained oral contraceptive use. Highest risk is in post-menopausal women. It is also associated with a personal history of breast, endometrial,


and colon cancers.

Diet Dietary fat may increase the risk.

Special Notes Mean age-adjusted incidence rate across health districts: 95% confidence interval on the mean age-adjusted incidence rate: Median age-adjusted incidence rate of health districts: Range of age-adjusted incidence rate for health districts: SEER rate (1998, Whites): 15.6 10.9 - 20.4 14.7 Range of age-adjusted incidence rate for health districts: 9.5 - 27.3 SIER rate (1998, Whites): 17.2

There were few cases of ovarian cancer among persons aged less than 20 years. The age-specific incidence rates of ovarian cancer increased with age starting in the 15-19 age group. The highest age-specific rate was for women aged 80-84. Health District 6 had statistically significantly more cases of ovarian cancer than expected based upon rates for the remainder of Idaho (p<0.01).






PANCREAS

Incidence and Mortality Summary							
Age-adjusted incidence rate per 100,000	Total	Male	Female				
	7.8	8.1	7.4				
# of new invasive cases	92	43	49				
# of new in-situ cases	0	0	0				
# of deaths	110	46	64				

Total Cases By County

Ada	24	Cassia	2	Lewis	-
Adams	-	Clark	-	Lincoln	-
Bannock	6	Clearwater	-	Madison	1
Bear Lake	1	Custer	-	Minidoka	2
Benewah	1	Elmore	-	Nez Perce	1
Bingham	1	Franklin	-	Oneida	1
Blaine	-	Fremont	-	Owyhee	-
Boise	-	Gem	-	Payette	-
Bonner	6	Gooding	1	Power	-
Bonneville	7	Idaho	1	Shoshone	1
Boundary	-	Jefferson	1	Teton	-
Butte	-	Jerome	1	Twin Falls	9
Camas	-	Kootenai	12	Valley	-
Canyon	8	Latah	-	Washington	3
Caribou	-	Lemhi	1		

Stage at Diagnosis - Pancreas





Risk and Associated Factors

Age Gender	Rates increase with age. It is rare in people younger than 40 years old. Incidence is slightly higher in males.
	· , ·
Race	In the United States, the incidence is higher in African Americans, Native Americans, and
	Hispanics, than in the population at large.
Diet	High dietary fat intake has been implicated as a potential risk factor.
Occupation	Persons in certain occupations are believed to be at higher risk, such as chemists, metal workers, and persons employed in the manufacture of benzidine and betanaphthylene.
Other	Pancreatic cancer is more common among smokers than non-smokers. Familial clustering has been observed in some studies. Pancreatic cancer usually progresses to an advanced stage before symptoms develop. It is rapidly fatal in over 90% of cases.

Special Notes		
Mean age-adjusted incidence rate across health districts:	7.2	
95% confidence interval on the mean age-adjusted incidence rate:	5.1 - 9.4	
Median age-adjusted incidence rate of health districts:	7.7	
Range of age-adjusted incidence rate for health districts:	1.7 - 10.9	
SEER rate (1998, Whites):	10.3	

There were few cases of pancreatic cancer among persons aged less than 45 years. The age-specific incidence rates of pancreatic cancer increased sharply from age groups 55-59 to 75-79. Health District 2 had statistically significantly fewer cases than expected based upon rates for the remainder of Idaho (p<0.05).





PROSTATE


Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	-	171.6	-				
# of new invasive cases	-	927	-				
# of new in-situ cases	-	1	-				
# of deaths	-	160	-				

Total Cases By County

Other

Ada	203	Cassia	13	Lewis	9
Adams	2	Clark	-	Lincoln	4
Bannock	36	Clearwater	9	Madison	8
Bear Lake	6	Custer	7	Minidoka	13
Benewah	8	Elmore	13	Nez Perce	40
Bingham	17	Franklin	9	Oneida	4
Blaine	16	Fremont	5	Owyhee	3
Boise	6	Gem	7	Payette	9
Bonner	26	Gooding	9	Power	2
Bonneville	51	Idaho	12	Shoshone	5
Boundary	7	Jefferson	8	Teton	2
Butte	1	Jerome	14	Twin Falls	61
Camas	-	Kootenai	92	Valley	16
Canyon	80	Latah	28	Washington	5
Caribou	6	Lemhi	8		

Stage at Diagnosis - Prostate



Risk and Associated Factors


Age Race It is rarely diagnosed before age 50, and it is primarily a disease of older men.
African American males have a substantially higher rate than Caucasian males.
A family history of prostate cancer is associated with increased risk.


Diet Dietary fat has been implicated in some studies.

Environmental and familial factors may contribute to an increased incidence but no specific factor in these two groups of potential risk factors has been clearly identified. Three risk factors are well established: age, family history, and ethnic group/country of residence.

Special Notes	
Mean age-adjusted incidence rate across health districts: 95% confidence interval on the mean age-adjusted incidence rate:	159.8 139.5 - 180.1
Median age-adjusted incidence rate of health districts:	155.3
Range of age-adjusted incidence rate for health districts: SEER rate (1998, Whites):	128.7 - 197.9 149.2

The age-specific incidence rate distribution of prostate cancer in Idaho in 2000 is similar to that reported by the National Cancer Institute's SEER program. There were no cases of prostate cancer among persons aged less than 40 years. The age-specific incidence rates of prostate cancer increased with age, peaking in the 70-74 age group. Health District 4 had statistically significantly more cases than expected (p<0.01), and Health Districts 3 and 6 had statistically significantly fewer cases based upon rates for the remainder of Idaho (p<0.01).






RECTUM

Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	13.1	15.8	11.1				
# of new invasive cases	156	85	71				
# of new in-situ cases	6	3	3				
# of deaths	33	21	12				

Stage at Diagnosis - Rectum and Rectosigmoid
--



Total Cases By County

Ada	31	Cassia	8	Lewis	-
Adams	2	Clark	-	Lincoln	-
Bannock	7	Clearwater	1	Madison	1
Bear Lake	-	Custer	1	Minidoka	2
Benewah	1	Elmore	2	Nez Perce	6
Bingham	5	Franklin	-	Oneida	-
Blaine	2	Fremont	2	Owyhee	-
Boise	1	Gem	-	Payette	2
Bonner	7	Gooding	2	Power	-
Bonneville	13	Idaho	2	Shoshone	2
Boundary	3	Jefferson	2	Teton	1
Butte	-	Jerome	1	Twin Falls	13
Camas	-	Kootenai	13	Valley	-
Canyon	20	Latah	2	Washington	3
Caribou	-	Lemhi	2		

Risk and Associated Factors

Age Rates increase with age and the vast majority of cases occur after age 50.

Gender Genetics Incidence rates are higher in males.

Specific genetic alterations have been recognized in several hereditary conditions with high risk of rectal cancer. These conditions account for about six percent of rectal cancer cases.

Diet

Strong evidence exists that diets high in fat and low in fiber contribute to increased risk of

rectal cancer.

Other

Individuals with a close family history of this cancer and those with a personal history of certain other cancers are at increased risk. Regular, moderate physical activity is associated with lower rates of this cancer.

		Special Notes

Mean age-adjusted incidence rate across health districts:

95% confidence interval on the mean age-adjusted incidence rate:

10.5 - 15.3

Median age-adjusted incidence rate of health districts:


13.9


Range of age-adjusted incidence rate for health districts:

8.6 - 16.9

SEER rate (1998, Whites):


There were few cases of rectal cancer among persons aged less than 45 years. The age-specific incidence rates of rectal cancer generally increased with age, peaking in the 85+ age group for males and 80-84 for females. No health districts had statistically significantly more, or fewer, cases than expected based upon rates for the remainder of Idaho.






STOMACH

Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	5.3	5.9	4.8				
# of new invasive cases	62	32	30				
# of new in-situ cases	1	0	1				
# of deaths	40	26	14				



5	Cassia	-	Lewis	
-	Clark	-	Lincoln	
6	Clearwater	-	Madison	
-	Custer	1	Minidoka	
2	Elmore	1	Nez Perce	2
2	Franklin	1	Oneida	
-	Fremont	-	Owyhee	1
-	Gem	2	Payette	4
1	Gooding	-	Power	
7	Idaho	-	Shoshone	5
-	Jefferson	1	Teton	
-	Jerome	1	Twin Falls	3
-	Kootenai	5	Valley	1
4	Latah	4	Washington	1
1	Lemhi	-		
	6 - 2 2 - 1 7 4	- Clark 6 Clearwater - Custer 2 Elmore 2 Franklin - Fremont - Gem 1 Gooding 7 Idaho - Jefferson - Jerome - Kootenai 4 Latah	- Clark - 6 Clearwater Custer 1 2 Elmore 1 2 Franklin 1 - Fremont Gem 2 1 Gooding - 7 Idaho Jefferson 1 - Jerome 1 - Kootenai 5 4 Latah 4	- Clark - Lincoln 6 Clearwater - Madison - Custer 1 Minidoka 2 Elmore 1 Nez Perce 2 Franklin 1 Oneida - Fremont - Owyhee - Gem 2 Payette 1 Gooding - Power 7 Idaho - Shoshone - Jefferson 1 Teton - Jerome 1 Twin Falls - Kootenai 5 Valley 4 Latah 4 Washington

Stage at Diagnosis - Stomach



Risk and Associated Factors

Age Rates increase with age.

Gender Incidence rates for males are usually more than twice as high as for females.

Race & SES There is a higher incidence in African Americans, as well as Asians, and incidence is also

higher in lower income groups.

Diet Increased risk has been attributed to diets high in smoked foods and foods high in nitrates.

Diets high in fresh fruits and vegetables seem to be protective.

Occupation Elevated rates have been found in certain occupational groups, especially coal miners and


asbestos workers.


Other Stomach cancer has recently been linked to peptic ulcer disease and to certain bacteria

associated with increased risk for both diseases.

Special Notes	
Mean age-adjusted incidence rate across health districts:	5.3
95% confidence interval on the mean age-adjusted incidence rate:	3.8 - 6.7
Median age-adjusted incidence rate of health districts:	6.5
Range of age-adjusted incidence rate for health districts:	2.3 - 6.9
SEER rate (1998, Whites):	7.4

There were no cases of stomach cancer among persons aged less than 40 years. The age-specific incidence rates of stomach cancer increased with age, peaking in the 75-79 age group for males and 80-84 for females. Health District 4 had statistically significantly fewer cases than expected based upon rates for the remainder of Idaho (p<0.05).






TESTIS

Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	-	6.9	-				
# of new invasive cases	-	43	-				
# of new in-situ cases	-	0	-				
# of deaths	-	2	-				

Total Cases By County

Ada	15	Cassia	-	Lewis	-
Adams	-	Clark	-	Lincoln	-
Bannock	5	Clearwater	-	Madison	-
Bear Lake	-	Custer	-	Minidoka	3
Benewah	-	Elmore	3	Nez Perce	1
Bingham	-	Franklin	-	Oneida	-
Blaine	-	Fremont	-	Owyhee	-
Boise	-	Gem	1	Payette	1
Bonner	-	Gooding	1	Power	-
Bonneville	2	Idaho	-	Shoshone	-
Boundary	-	Jefferson	1	Teton	-
Butte	-	Jerome	1	Twin Falls	1
Camas	-	Kootenai	5	Valley	-
Canyon	1	Latah	1	Washington	-
Caribou	-	Lemhi	1		

Stage at Diagnosis - Testis




Risk and Associated Factors


Age This is the most common cancer in young males, especially males between the ages of 20 and 34.

Race Other Incidence rates are substantially higher in Caucasian males than in African American males. Undescended testis, a minor abnormality that can usually be detected and corrected with surgery in childhood, is responsible for a substantially high risk for testicular cancer when uncorrected. The extent to which surgical correction reduces cancer risk is unclear. Some evidence suggests that males exposed in utero to diethylstilbestrol (DES) are at increased risk. With current treatment the cure rates for testicular cancer are greater than 80%.

Special Notes	
Mean age-adjusted incidence rate across health districts:	6.3
95% confidence interval on the mean age-adjusted incidence rate:	4.8 - 7.9
Median age-adjusted incidence rate of health districts:	6.6
Range of age-adjusted incidence rate for health districts:	3.5 - 9.2
SEER rate (1998, Whites):	6.3

There were few cases of testicular cancer among persons aged 50-84 years. The highest age-specific incidence rate was in the 40-44 age group. Health District 4 had statistically significantly more cases than expected based upon rates for the remainder of Idaho (p<0.05).






THYROID

Incidence and Mortality Summary							
	Total	Male	Female				
Age-adjusted incidence rate per 100,000	6.8	2.5	11.0				
# of new invasive cases	84	15	69				
# of new in-situ cases	0	0	0				
# of deaths	1	1	0				

Ada	31	Cassia	_	Lewis	_
Adams	-	Clark	-	Lincoln	-
Bannock	4	Clearwater	1	Madison	1
Bear Lake	-	Custer	-	Minidoka	-
Benewah	-	Elmore	-	Nez Perce	2
Bingham	3	Franklin	-	Oneida	-
Blaine	1	Fremont	-	Owyhee	-
Boise	-	Gem	-	Payette	-
Bonner	-	Gooding	2	Power	-
Bonneville	7	Idaho	-	Shoshone	-
Boundary	2	Jefferson	3	Teton	-
Butte	-	Jerome	-	Twin Falls	9
Camas	-	Kootenai	9	Valley	-
Canyon	6	Latah	3	Washington	-
Caribou	-	Lemhi	-		

Stage at Diagnosis - Thyroid



Risk and Associated Factors

Though relatively unusual, it is still one of the most common malignancies affecting adoles-Age cents and adults up to 50 years of age.

Gender

Two-thirds of the cases are among females.

Race & SES Hormonal The incidence is higher in Caucasians and in upper income groups.

Hormonal factors are believed to contribute to the increased risk in females. This is demon-


strated by the sharp increase in incidence among women after menarche.


Other

Occupational and environmental exposures to ionizing radiation have been associated with higher rates of thyroid cancer. Radiation exposure to the head and neck in childhood is a well-known risk factor. Family history of thyroid cancer substantially increases the risk. Death due to thyroid cancer under age 40 is rare. Prognosis worsens with each decade of age over 50.

Special Notes			
Mean age-adjusted incidence rate across health districts:	6.6		
95% confidence interval on the mean age-adjusted incidence rate:	5.1 - 8.2		
Median age-adjusted incidence rate of health districts:	6.6		
Range of age-adjusted incidence rate for health districts:	3.3 - 9.7		
SEER rate (1998, Whites):	6.6		

There were no cases of thyroid cancer among persons aged less than 15 years. The age-specific incidence rates of thyroid cancer were typically higher for females than males. Health District 4 had statistically significantly more cases than expected based upon rates for the remainder of Idaho (p<0.05).





SECTION II

STATE OF IDAHO - 2000 INCIDENCE DATA BY SITE AND GENDER

Idaho Resident Cancer Cases (in-situ) - 2000

Lip Tongue				ΓV
SOUTH SOUT	DDIMARY SITE OF CANCER	TOTAL		
BUCCAL CAVITY AND PHARYNX Ip				
Lip Trongue	OTAL NEW CANCER CASES (III-SILU)	555	229	304
Lip Trongue	DICCAL CAVITY AND DHARVNY	6	_	1
Trongue				
Major salvary glands (ma) and other mouth				0
Sum and other mouth				0
Nasophapinx			1	0
Orophaymx				1
Hypophapmx			1	0
Torisl and other buccal cavity DIGESTIVE SYSTEM			1	
DIGESTIVE SYSTEM			1	0
Esophagus	onsil and other buccal cavity	0	0	C
Esophagus				
Stomach				15
Small intestiene				1
Section Sect		1	1	1
Liver & bile duct Galibladder and other bililary	Small intestine	1	1	1
Liver & bile duct Galibladder and other bililary		14	5	9
Liver & bile duct Galibladder and other bililary	Rectum, rectosigmoid and anus	7	4] 3
Galibladder and other bililary	iver & bile duct	0	0	(
Pancreas Pentioneum and retroperitioneum O	Sallbladder and other biliary	0	0	 c
Peritoneum and retroperitoneum O	Pancreas	0	0	
Other digestive 0 0 RESPIRATORY SYSTEM 3 2 Lung and bronchus 0 0 Trachea, pleura, and other 0 0 SKIN 199 113 8 Melanoma of skin 199 113 8 Other skin cancers 0 0 113 8 BREAST 149 1 14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Peritoneum and retroperitoneum	0	0	c
RESPIRATORY SYSTEM Larynx Laryny Laryny Laryny Diagnatic processing and state of the plant		0	0	l c
Larynx				
Larynx	RESPIRATORY SYSTEM	3	2	1
Lung and bronchus 0 0 Trachea, pleura, and other 0 0 SKIN 199 113 8 Melanoma of skin 199 113 8 Other skin cancers 0 0 0 BREAST 149 1 14 FEMALE GENITAL SYSTEM 25 0 2 Cervix uteri (endometrium) 0 0 0 0 Ovary 0 0 0 0 0 Vagina 3 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				1
SKIN 199 113 8				Ö
SKIN 199 113 8 Melanoma of skin 199 113 8 Melanoma of skin 199 113 8 Melanoma of skin 199 113 8 199 113 8 199 113 8 199 113 8 199 113 8 199 113 8 199 113 8 199 113 8 199 113 199			1	l
Melanoma of skin 199	radica, picara, and other	1	Ĭ	Ĭ
Melanoma of skin 199	NIN .	100	112	86
Other skin cancers 0				86
BREAST				
FEMALE GENITAL SYSTEM	other skin cancers	1 0	1	0
FEMALE GENITAL SYSTEM	NE ACT	4.40		4.40
Cervix uteri	REAST	149	1	148
Cervix uteri	TAMALE OF WITH OVOTEN	0.5		0.5
Corpus uteri (endometrium) 4 0 Ovary 0 0 Vagina 3 0 Vulva 17 0 1 Uterus, NOS and other female genital organs 1 0 1 MALE GENITAL SYSTEM 2 2 2 Prostate gland 1 <td></td> <td></td> <td></td> <td>-</td>				-
Ovary 0 0 Vagina 3 0 Vulva 17 0 1 Uterus, NOS and other female genital organs 1 0 1 MALE GENITAL SYSTEM 2 2 2 Prostate gland 1 2 2 2 2 <			1	n/a
Vagina 3 0 Vulva 17 0 1 Ulterus, NOS and other female genital organs 1 0 1 MALE GENITAL SYSTEM 2 2 2 Prostate gland 1 2 2 2 2 2 1 2				4
Vulva 17 0 1 Uterus, NOS and other female genital organs 1 0 1 MALE GENITAL SYSTEM 2 2 2 2 Prostate gland 1				0
Uterus, NOS and other female genital organs	· ·			3
MALE GENITAL SYSTEM Prostate gland 1 1 1 Testis		17		17
Prostate gland	Iterus, NOS and other female genital organs	1	0	1
Prostate gland				
Testis 0 0 0 Penis and other male genital organs 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		2	2	0
Penis and other male genital organs	Prostate gland	1	1	0
URINARY SYSTEM Urinary bladder Kidney and renal pelvis Ureter and other urinary organs LYMPHATIC AND HEMATOPOIETIC TISSUE Hodgkin's lymphoma Non-Hodgkins lymphoma Non-Hodgkins lymphoma Non-Hodgkins lymphoma O Kuttiple myeloma Acute lymphocytic Chronic lymphocytic O Chronic Myeloid O Other OTHER OR UNKNOWN SITES Eye Brain Other nervous system Other nervous system Other nervous system Other nervous system O Other nervous and joints O Other sold in the system of t	estis	0	0	0
Urinary bladder 115 89 2 Kidney and renal pelvis 3 2 Ureter and other urinary organs 4 3 LYMPHATIC AND HEMATOPOIETIC TISSUE 0 0 Hodgkin's lymphoma 0 0 Non-Hodgkins lymphoma 0 0 Multiple myeloma 0 0 Acute lymphocytic 0 0 Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0	enis and other male genital organs	1	1	0
Urinary bladder 115 89 2 Kidney and renal pelvis 3 2 Ureter and other urinary organs 4 3 LYMPHATIC AND HEMATOPOIETIC TISSUE 0 0 Hodgkin's lymphoma 0 0 Non-Hodgkins lymphoma 0 0 Multiple myeloma 0 0 Acute lymphocytic 0 0 Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0			I	
Kidney and renal pelvis 3 2 Ureter and other urinary organs 4 3 LYMPHATIC AND HEMATOPOIETIC TISSUE 0 0 Hodgkin's lymphoma 0 0 Non-Hodgkins lymphoma 0 0 Multiple myeloma 0 0 Acute lymphocytic 0 0 Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0	JRINARY SYSTEM	122	94	28
Kidney and renal pelvis 3 2 Ureter and other urinary organs 4 3 LYMPHATIC AND HEMATOPOIETIC TISSUE 0 0 Hodgkin's lymphoma 0 0 Non-Hodgkins lymphoma 0 0 Multiple myeloma 0 0 Acute lymphocytic 0 0 Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0	Jrinary bladder	115		26
Ureter and other urinary organs				
LYMPHATIC AND HEMATOPOIETIC TISSUE 0 0				
Hodgkin's lymphoma	. •	1	I	l ·
Hodgkin's lymphoma	YMPHATIC AND HEMATOPOIETIC TISSUE	0	0	0
Non-Hodgkins lymphoma 0 0 Multiple myeloma 0 0 Acute lymphocytic 0 0 Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0				
Multiple myeloma 0 0 Acute lymphocytic 0 0 Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0				l
Acute lymphocytic 0 0 Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0				
Chronic lymphocytic 0 0 Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0			1	
Acute Myeloid 0 0 Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0			1	
Chronic Myeloid 0 0 Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0			1	
Other 0 0 OTHER OR UNKNOWN SITES 0 0 Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0				
OTHER OR UNKNOWN SITES Eye 0 Brain 0 Other nervous system Thyroid gland Other endocrine Bones and joints Soft tissue (including heart) 0 0 0 0 0 0 0 0 0 0 0 0 0			1	
Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0	AUICI	I "	ľ	C
Eye 0 0 Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0	OTHER OR LINUXIONAL CITES			
Brain 0 0 Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0				
Other nervous system 0 0 Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0			1	0
Thyroid gland 0 0 Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0			1	
Other endocrine 0 0 Bones and joints 0 0 Soft tissue (including heart) 0 0				
Bones and joints 0 0 Soft tissue (including heart) 0 0			1	
Bones and joints 0 0 Soft tissue (including heart) 0 0			1	0
Soft tissue (including heart) 0 0		0	0	0
		0	0	C
Other sites, III-defined sites or unknown sites 0 0 0		1 0	0	

Idaho Resident Cancer Cases (invasive) - 2000

idano nesident Cancer Cases (invasive)	- 2000	0.0	X
PRIMARY SITE OF CANCER	TOTAL	Male	Female
TOTAL NEW CANCER CASES (invasive)	5,223	2,749	2,473
TOTAL NEW OFFICER OFFICE (III AGITO)	0,220	2,7 10	2,110
BUCCAL CAVITY AND PHARYNX	147	99	48
Lip	41	34	7
Tongue	22	14	
Major salivary glands	21	12	9
Gum and other mouth	16	7	8 9 2 2
Nasopharynx	6	4	2
Oropharynx	4	2	2
Hypopharynx	5	4	1
Tonsil and other buccal cavity	32	22	10
DIGESTIVE SYSTEM	889	449	440
Esophagus	69	51	18
Stomach	62	32	30
Small intestine	27	14	13
Colon excluding rectum	390	178	212
Rectum, rectosigmoid and anus	171	91	80
Liver & bile duct	32	22	10
Gallbladder and other biliary	28	12	16
Pancreas	92	43	49
Peritoneum and retroperitoneum	13	4	9
Other digestive	5	2	3
RESPIRATORY SYSTEM	739	457	282
Larynx	35	32	3
Lung and bronchus	692	418	274
Trachea, pleura, and other	12	7	5
SKIN	241	143	97
Melanoma of skin	234	139	94
Other skin cancers	7	4	3
		Ì	_
BREAST	834	8	826
FEMALE GENITAL SYSTEM	294	0	294
Cervix uteri	39	0	39
Corpus uteri (endometrium)	137	0	137
Ovary	98	0	98
Vagina	3	0	3
Vulva	8	0	8
Uterus, NOS and other female genital organs	9	0	9
MALE GENITAL SYSTEM	977	977	0
Prostate gland	927	927	0
Testis	43	43	0
Penis and other male genital organs	7	7	0
URINARY SYSTEM	284	198	96
Urinary bladder			86
Kidney and renal pelvis	145 134	117 78	28 56
Ureter and other urinary organs	5	3	2
o o o o and o o o o o o o o o o o o o o o o o o o	· ·	, and the second	_
LYMPHATIC AND HEMATOPOIETIC TISSUE	451	252	199
Hodgkin's lymphoma	28	20	8
Non-Hodgkins lymphoma	231	118	113
Multiple myeloma	56	33	23
Acute lymphocytic leukemia	19	8	11
Chronic lymphocytic leukemia	35	21	14
Acute myeloid leukemia	38	23	15
Chronic myeloid leukemia Other leukemia	25 19	15 14	10 5
OTHER OR UNKNOWN SITES	367	166	201
Eye	5	2	3
Brain Other persons system	86	52	34
Other nervous system	4	2	2
Thyroid gland Other endocrine	84 3	15	69
Bones and joints	14	3 5	0
Soft tissue (including heart)	43	20	23
Other sites, Ill-defined sites or unknown sites	128	67	61
Outer sites, in definited sites of unknown sites	120	07	01

SECTION III

STATE OF IDAHO - 2000 MORTALITY DATA BY SITE AND GENDER

Idaho Resident Cancer Deaths - 2000

ICD-10			SEX	
CODE	SITE OF MALIGNANT NEOPLASM	TOTAL	Male	Female
C00-C97	TOTAL MALIGNANT NEOPLASM DEATHS	2,131	1,128	1,003
C00-C14	LIP, ORAL CAVITY AND PHARYNX	38	22	16
C00 C01-C02 C10-C13, C14.0 C03-C09, C14.2-C14.8	Lip Tongue Pharynx Other and unspecified sites within the lip, oral cavity, and pharynx	- 8 15	- 4 14	- 4 1
C15-C26	DIGESTIVE ORGANS	457	249	208
C15 C16 C17 C18 C19-C20 C21 C22.0, C22.2-C22.9 C22.1 C23-C24 C25 C26	Esophagus Stomach Small intestine Colon Rectosigmoid junction and rectum Anus and anal canal Liver Intrahepatic bile duct Gallbladder and extrahepatic bile ducts Pancreas Other and ill-defined digestive organs	47 40 6 152 33 3 31 13 13 110 9	34 26 5 70 21 - 26 8 7 46 6	13 14 1 82 12 3 5 5 6 64 3
C30-C39	RESPIRATORY AND INTRATHORACIC ORGANS	557	332	225
C30-C31 C32 C33-C34 C37-C38 C39	Nasal cavity, middle ear, and accessory sinuses Larynx Trachea, bronchus, and lung Thymus, heart, mediastinum, and pleura Other and ill-defined sites in the respiratory system and intrathoracic organs	2 16 538 1	15 316 1	2 1 222 -
C40-C41	BONE AND ARTICULAR CARTILAGE	5	1	4
C43-C44 C43 C44	MELANOMA AND OTHER MALIGNANT NEOPLASMS OF SKIN Melanoma of skin Other malignant neoplasms of skin	51 37 14	33 22 11	18 15 3
C45-C49	MESOTHELIAL AND SOFT TISSUE		21	13
C45-C49 C45 C46 C47-C49	Mesothelioma Kaposi's sarcoma Other mesothelial and soft tissue	34 13 - 21	8 - 13	5 - 8
C50	BREAST	179	1	178
C51-C58	FEMALE GENITAL ORGANS	103	-	103
C51-C52 C53 C54-C55 C56 C57 C58	Vulva and vagina Cervix uteri Corpus uteri and uterus, part unspecified Ovary Other and unspecified female genital organs Placenta	5 10 22 65 1	- - - - -	5 10 22 65 1

Idaho Resident Cancer Deaths - 2000

ICD-10			SEX	
CODE	SITE OF MALIGNANT NEOPLASM	TOTAL	Male	Female
C60-C63	MALE GENITAL ORGANS	164	164	-
C61	Prostate	160	160	-
C62 C60, C63	Testis Penis and other and unspecified male genital organs	2 2	2	-
C60, C63	Penis and other and unspecified male genital organs		2	-
C64-C68	URINARY TRACT	100	62	38
C64-C65	Kidney and renal pelvis	46	24	22
C67	Bladder	53	37	16
C66, C68	Other and unspecified sites within the urinary tract	1	1	-
C69	EYE AND ADNEXA	-	-	-
C70-C72	MENINGES, BRAIN, AND OTHER PARTS OF CENTRAL			
	NERVOUS SYSTEM	67	39	28
C71	Brain	66	39	27
C70, C72	Other parts of central nervous system	1	-	1
C73-C75	THYROID AND OTHER ENDOCRINE GLANDS	3	3	-
C76-C80, C97	OTHER MALIGNANT NEOPLASMS OF OTHER AND			
	UNSPECIFIED SITES	126	63	63
C81-C96	LYMPHOID, HEMATOPOIETIC, AND RELATED TISSUE	247	138	109
C81	Hodgkin's disease	6	2	4
C82-C85	Non-Hodgkin's lymphoma	108	53	55
C88	Malignant immunoproliferative diseases	2	2	-
C90	Multiple myeloma and malignant plasma cell neoplasms	41	27	14
C91 C92	Lymphoid leukemia Myeloid leukemia	31 41	19 26	12 15
C92	Monocytic leukemia	- 41		-
C94-C95	Other and unspecified leukemia	18	9	9
C96	Other and unspecified malignant neoplasms of lymphoid, hematopoietic, and related tissue	-	-	-

^{*} Source: Idaho Bureau of Vital Records and Health Statistics, Idaho Department of Health and Welfare. 13

The manner of coding the underlying cause of death changed in 1999 from the ninth revision (ICD-9) to the tenth revision of the International Classification of Diseases (ICD-10). The introduction of ICD-10 resulted in a major reclassification of all causes of death from a numeric classification to an alphanumeric classification. The tenth revision also resulted in new titles for causes, the inclusion of terms and titles from one category to another, regroupings of diseases, and modifications of the coding rules. The introduction of ICD-10 created discontinuities in trend data for some causes of death; therefore, the numbers of deaths in 1999 and later years by site of malignant neoplasm may not be comparable to previously published data for numbers of deaths by site for years prior to 1999. The extent of the discontinuity is measured using a comparability ratio. The National Center for Health Statistics has constructed comparability ratios for the leading causes of death to measure the discontinuity between the data tabulated by the tenth revision and data tabulated by the ninth revision. The comparability ratio for malignant neoplasms based on ICD-10 (codes C00-C97) to ICD-9 (codes 140-208) is 1.01. For more information on ICD, comparability ratios, or Idaho cancer mortality trends, contact the Bureau of Vital Records and Health Statistics, Idaho Department of Health and Welfare, at (208) 334-6658.

SECTION IV

2000 AGE SPECIFIC INCIDENCE RATES PER 100,000 POPULATION BY SITE AND GENDER

Page 70

						i												
		6	- 14	- 19	- 24	- 29	- 34	- 39	- 44	- 49	- 54	- 59	- 64	69 -	- 74	- 79	- 84	_
Age (years)	< 5	5 -	10	15	20	25	30	35	40	45	20	55	09	65	20	75	80	85+
						i												
All Cancers													11000					
All	16.4	10.9	14.3	16.2	28.7	50.5	71.2	120.1	189.7	315.7	500.8	846.3		1720.2	2178.7	2351.9	2494.6	2043.5
Male	14.0	11.6	18.6	12.5	22.5	49.9	55.7	106.4	136.3	224.7	412.7	991.7	1333.3	2132.4	2826.8	2959.3	3252.6	3143.3
Female	18.9	10.2	9.8	20.1	35.5	51.2	87.4	134.1	241.3	407.6	591.0	701.6	1053.5	1332.9	1607.7	1882.0	1980.3	1498.8
Bladder																		
All	0.0	0.0	0.0	0.0	0.0	1.2	1.2	2.1	5.1	9.8	17.9	30.0	58.9	87.1	114.5	141.3	144.6	177.2
Male	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	6.1	15.1	32.9	50.1	92.5	174.7	167.0	263.6	265.3	401.3
Female	0.0	0.0	0.0	0.0	0.0	2.4	2.4	0.0	4.1	4.4	2.6	10.0	25.3	4.8	68.3	46.6	62.6	66.3
Brain						i												
All	2.1	3.0	1.0	1.8	1.1	4.7	4.7	7.4	8.2	6.5	9.0	6.7	14.7	14.9	30.7	16.4	23.3	16.6
Male	2.0	0.0	1.9	1.8	0.0	9.1	4.6	10.4	10.2	10.8	12.7	13.4	8.4	20.6	47.7	15.1	34.6	0.0
Female	2.1	6.1	0.0	1.8	2.2	0.0	4.9	4.3	6.1	2.2	5.2	0.0	21.1	9.7	15.8	17.5	15.7	24.8
Breast																		
Female	0.0	0.0	0.0	1.8	0.0	12.2	29.1	44.7	94.1	189.6	259.2	286.0	332.9	400.8	562.2	536.0	571.4	281.6
Cervix Uteri																		
Female	0.0	0.0	0.0	0.0	0.0	0.0	2.4	10.6	12.3	17.4	10.4	16.6	12.6	9.7	15.8	5.8	7.8	0.0
Colon																		
All	0.0	0.0	0.0	0.0	0.0	0.0	1.2	7.4	5.1	11.9	23.1	40.0	71.6	129.5	164.8	246.4	270.5	254.8
Male	0.0	0.0	0.0	0.0	0.0	0.0	2.3	6.3	8.1	13.0	15.2	43.4	79.9	118.2	190.8	218.4	311.4	250.8
Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.5	2.0	10.9	31.1	36.6	63.2	140.1	141.9	268.0	242.6	256.7
Endometrium																		
Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.4	21.8	54.4	56.5	80.1	72.4	73.6	52.4	133.1	49.7
Esophagus																		
All	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.0	3.3	6.4	18.3	21.1	14.9	22.4	42.7	32.6	22.2
Male	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.0	6.5	12.7	36.7	29.4	10.3	29.8	67.8	57.7	33.4
Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.6	19.3	15.8	23.3	15.7	16.6
Hodgkin's Lymphoma																		
All	1.0	0.0	1.9	0.9	4.3	4.7	3.6	3.2	1.0	1.1	1.3	1.7	6.3	0.0	0.0	0.0	4.7	11.1
Male	2.0	0.0	1.9	1.8	6.1	9.1	4.6	2.1	2.0	2.2	0.0	0.0		0.0	0.0	0.0	0.0	33.4
Female	0.0	0.0	2.0	0.0	2.2	0.0	2.4	4.3	0.0	0.0	2.6	3.3	0.0	0.0	0.0	0.0	7.8	0.0

Dec	IDAHO	AC	SE SP	ECIFIC	CANO	CER R	ATES	, PER 1	00,000	POPUL	ATION,	BY SI	TE AND	GENDE	R			2000	
December 2	Age (years)	۷ 5	5 - 9	10 - 14	15 - 19	20 - 24	25 - 29	30 - 34	35 - 39	40 - 44	45 - 49	50 - 54	55 - 59	60 - 64	62 - 69	70 - 74	75 - 79	80 - 84	85+
2001	Kidney & Renal Pelvis						i												
	All	2.1	0.0	0.0	1.8	0.0	1.2	0.0	2.1	6.1	6.5	6.4	40.0	37.9	47.3	53.1	49.3	32.6	44.3
	Male	0.0	0.0	0.0	1.8	0.0	0.0	0.0	4.2	8.1	8.6	7.6	50.1	42.1	56.5	71.6	52.7	46.1	83.6
	Female	4.2	0.0	0.0	1.8	0.0	2.4	0.0	0.0	4.1	4.4	5.2	29.9	33.7	38.6	36.8	46.6	23.5	24.8
	Larynx						į												
	All	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	1.1	1.3	8.3	2.1	7.5	25.1	26.3	9.3	11.1
	Male	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	2.2	2.5	13.4	4.2	10.3	53.7	52.7	23.1	33.4
	Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	4.8	0.0	5.8	0.0	0.0
	Leukemia	0.4	4.0						4.0			40.0	40.0	40.0		00.5	20.4	00.0	22.2
	All Male	6.1	4.0 3.9	2.9 5.6	2.7 3.6	1.1 0.0	0.0	3.6 4.6	4.2 8.3	4.1 4.1	2.2 2.2	10.3 15.2	10.0 10.0	19.0 16.8	39.8 56.5	33.5 41.8	82.1 105.4	88.6 138.4	60.9 100.3
a	Female	8.4	3.9 4.1	0.0	1.8	2.2	0.0	2.4	0.0	4.1	2.2	5.2	10.0	21.1	24.2	26.3	64.1	54.8	41.4
Cancer in		0.1		0.0	1.0	2.2	0.0	2.1	0.0		۷.۲	0.2	10.0	21.1	21.2	20.0	0 1.1	01.0	
7	Liver & Bile Duct					0.0				4.0				40.5	440	440	10.1	4 -	
7 (All	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1 2.1	1.0 2.0	2.2 4.3	2.6 2.5	3.3 3.3	10.5	14.9	14.0 17.9	16.4	4.7	5.5 16.7
Idaho	Male Female	0.0	0.0	0.0	0.0 0.0	0.0	0.0	0.0	2.1	0.0	0.0	2.5	3.3	21.0 0.0	10.3 19.3	17.9	30.1 5.8	11.5 0.0	0.0
- 07	1 cmale	0.0	0.0	0.0	0.0	0.0	0.01	0.0	2.1	0.0	0.0	2.0	0.01	0.0	13.3	10.5	5.0	0.0	0.0
2000	Lung & Bronchus					0.0				10.0	40.4	05.0	101.0	4.40.4	044.0	200.0		004.7	004.5
9	All	0.0	0.0	0.0	0.0 0.0	0.0	2.4 0.0	2.4 4.6	1.1 0.0	10.2 12.2	18.4 19.4	35.9 43.0	101.6 133.6	143.1 143.0	311.2 400.8	388.3 530.8	377.8 512.1	391.7 611.3	221.5 367.8
\neg	Male Female	0.0	0.0	0.0	0.0	0.0	4.9¦	0.0	2.1	8.2	19.4	43.0 28.5	69.8	143.0	400.8 227.0	262.7	273.8	242.6	367.8 149.1
		0.0	0.0	0.0	0.0	0.0	7.0	0.0	2.1	0.2	17.4	20.0	00.0	140.0	227.0	202.7	210.0	242.0	140.1
	Melanoma of the Skin		0.0	0.0	0.7	0.0	4 7	7.4	00.0	45.0	04.5	04.0	00.7	40.4	47.0	50.4	75.0	00.0	00.5
	All Male	0.0	0.0	0.0	2.7 3.6	3.2 2.0	4.7 4.5	7.1 7.0	20.0 25.0	15.3 10.2	31.5 32.4	34.6 35.4	36.7 56.8	42.1 58.9	47.3 61.7	53.1 77.5	75.6 97.9	60.6 103.8	66.5 117.0
	Female	0.0	0.0	0.0	1.8	4.4	4.9¦	7.3	14.9	18.4	30.5	33.7	16.6	25.3	33.8	31.5	58.3	31.3	41.4
	Torrido	0.0	0.0	0.0	1.0			7.0			00.0	00.1	10.0	20.0	00.0	01.0	00.0	01.0	
	Myeloma																		
	All	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	3.8	10.0	16.8	7.5	27.9	29.6	42.0	33.2
	Male	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	10.0	21.0	15.4	41.8	30.1	57.7	66.9
اص	Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	2.6	10.0	12.6	0.0	15.8	29.1	31.3	16.6
Page	Non-Hodgkin's Lymphoma																		
71	All	1.0	2.0	1.9	0.9	2.1	3.5	4.7	10.5	9.2	15.2	21.8	31.7	31.6	77.2	72.6	108.4	88.6	127.4
_	Male Female	2.0	3.9 0.0	1.9 2.0	0.0 1.8	4.1 0.0	4.5 2.4	2.3 7.3	12.5 8.5	10.2 8.2	13.0 17.4	30.4 13.0	33.4 29.9	25.2 37.9	87.4 67.6	77.5 68.3	113.0 104.9	103.8 78.3	167.2 107.7
	геттане	1 0.0	0.0	2.0	1.0	0.0	4.4¦	1.3	0.5	0.2	17.4	13.0	29.9	31.9	07.0	00.3	104.9	10.3	107.7

IDAHO

AGE SPECIFIC CANCER RATES, PER 100,000 POPULATION, BY SITE AND GENDER

2000

	T											:						
		စ	- 14	- 19	- 24	- 29	- 34	- 39	- 44	- 49	- 54	- 59	- 64	- 69	- 74	- 79	- 84	_
Age (years)	۸ 5	5 -	10	15	20	25	30	35	40	45	50	55	09	65	20	75	80	85+
Oral Cavity & Pharynx												i						
All	0.0	0.0	1.0	0.0	0.0	1.2	0.0	2.1	6.1	9.8	16.7	26.7	44.2	47.3	67.0	42.7	28.0	88.6
Male	0.0	0.0	0.0	0.0	0.0	2.3	0.0	2.1	8.1	13.0	15.2	36.7	63.1	77.1	107.4	67.8	34.6	167.2
Female	0.0	0.0	2.0	0.0	0.0	0.0	0.0	2.1	4.1	6.5	18.2	16.6	25.3	19.3	31.5	23.3	23.5	49.7
Ovary																		
Female	0.0	0.0	3.9	0.0	2.2	4.9	12.1	8.5	16.4	26.2	33.7	16.6	50.6	53.1	21.0	29.1	62.6	49.7
Pancreas																		
All	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	2.0	4.3	10.3	11.7	10.5	24.9	30.7	55.8	74.6	60.9
Male	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	2.0	2.2	12.7	10.0	12.6	30.8	29.8	67.8	69.2	50.2
Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	6.5	7.8	13.3	8.4	19.3	31.5	46.6	78.3	66.3
Prostate																		
Male	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	10.2	28.1	103.8	407.4	517.4	847.8	1133.1	994.0	991.9	819.3
Rectum & Rectosigmoid																		
All	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.0	10.9	10.3	26.7	71.6	29.9	67.0	65.7	69.9	83.1
Male	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	13.0	7.6	30.1	84.1	36.0	89.5	67.8	69.2	150.5
Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	8.7	13.0	23.3	59.0	24.2	47.3	64.1	70.4	49.7
Stomach																		
All	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	10.3	10.0	16.8	24.9	33.5	26.3	28.0	16.6
Male Female	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0 0.0	0.0	15.2 5.2	6.7 13.3	16.8 16.9	20.6 29.0	35.8 31.5	45.2 11.7	11.5 39.1	33.4 8.3
remale	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	13.3	10.9	29.0	31.3	11.7	39.1	0.3
Testis																		
Male	2.0	0.0	0.0	0.0	10.2	15.9	11.6	14.6	18.3	13.0	0.0	3.3	0.0	0.0	6.0	0.0	0.0	16.7
Thyroid												i						
All	0.0	0.0	0.0	1.8	8.5	4.7	5.9	10.5	15.3	7.6	16.7	3.3	4.2	5.0	8.4	19.7	14.0	11.1
Male	0.0	0.0	0.0	0.0	0.0	0.0	4.6	2.1	2.0	0.0	15.2	3.3	8.4	0.0	0.0	15.1	0.0	0.0
Female	0.0	0.0	0.0	3.7	17.8	9.8	7.3	19.2	28.6	15.3	18.2	3.3	0.0	9.7	15.8	23.3	23.5	16.6

SECTION V

2000 OBSERVED VS. EXPECTED NUMBERS BY HEALTH DISTRICT

2000 OBSERVED VERSUS EXPECTED NUMBERS BY HEALTH DISTRICT

ALL SEXES

	Н	D 1	Н	D 2	ŀ	ID 3	H	ID 4	Н	ID 5	I	HD 6	H	1D 7
	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	S EXP	OBS	EXP
All Sites	931	829.2*	460	490.9	754	824.1+	1344	1207.9*	700	740.3	499	635.8*	542	597.7+
Bladder	52	39.4+	31	23.9	33	41.8	64	56.9	30	37.6	24	31.1	25	28.8
Brain	13	13.0	8	7.1	10	13.4	24	21.6	9	11.7	8	10.3	12	9.5
Breast	141	130.8	68	75.2	113	126.4	226	191.7+	112	112.8	84	97.7	87	93.4
Cervix	6	6.1	5	3.1	5	5.7	10	10.5	8	4.6	2	4.7	3	4.6
Colon	71	59.9	41	36.6	63	60.6	83	88.7	44	57.1	42	45.9	42	42.4
Endometrium	27	21.0	11	12.6	22	20.3	34	31.9	17	18.9	11	16.5	13	15.5
Esophagus	13	10.7	5	6.5	14	10.0	14	16.6	8	9.8	7	8.1	6	7.9
Hodgkin's lymphoma	7	3.2+	1	2.4	2	4.6	10	6.6	4	3.4	0	3.8	4	3.2
Kidney and renal pelvis	18	22.1	13	12.1	21	20.2	36	30.1	17	18.5	13	16.0	15	15.1
Larynx	5	5.7	7	2.9+	3	5.8	6	8.5	6	4.7	6	3.8	2	4.1
Leukemia	26	19.6	13	12.0	23	20.8	31	31.6	19	18.8	10	16.9	14	15.4
Liver & bile duct	7	4.8	3	2.9	5	4.8	6	8.0	6	4.1	2	3.9	3	3.6
Lung and bronchus	140	105.4*	70	64.5	112	106.2	180	147.2*	86	99.1	41	86.0*	60	78.3+
Melanoma of skin	48	33.9+	17	20.4	27	35.5	62	56.5	30	30.9	18	27.9	15	27.6+
Myeloma	11	8.6	4	5.4	7	9.1	18	10.9+	7	8.0	4	6.8	4	6.4
Non-Hodgkin's lymphoma	42	35.0	15	21.5	38	34.8	51	55.8	26	32.6	31	26.3	25	25.7
Oral cavity and pharynx	28	22.6	3	14.4*	17	23.0	28	36.1	29	18.6+	19	16.7	10	16.9
Ovary	9	16.5	6	8.7	19	13.8	25	24.4	9	13.6	20	10.2*	10	11.0
Pancreas	20	13.5	2	9.4+	11	14.9	24	19.8	15	12.6	9	10.9	10	10.0
Prostate	138	152.7	98	85.6	106	149.6*	238	196.3*	128	130.1	81	111.5*	89	104.4
Rectum & rectosigmoid	26	25.0	10	15.0	27	23.3	31	36.4	26	21.1	12	18.9	22	16.6
Stomach	13	9.5	6	5.7	12	9.0	7	16.1+	4	9.3	9	7.0	9	6.6
Testis	5	5.9	2	3.5	3	6.7	18	10.1+	6	5.0	5	5.0	4	5.1
Thyroid	11	12.3	6	7.2	6	13.1	31	20.0+	12	10.3	7	10.1	11	9.7

Note: Observed and expected numbers exclude in-situ cases, basal/squamous skin cases, and cases with unknown age and/or gender.

⁺ Statistically significant difference at p=0.05 or less.

^{*} Statistically significant difference at p=0.01 or less.

2000 OBSERVED VERSUS EXPECTED NUMBERS BY HEALTH DISTRICT

MALES

	HD 1		HD 2		HD 3		F	1D 4	Н	D 5	Н	ID 6	Н	D 7
	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP
All Sites	478	455.6	259	268.4	394	438.0+	681	620.8+	391	396.4	269	339.3*	280	320.7+
Bladder	40	32.3		19.0+	26	32.9	49	43.9	25	30.0	16	25.1	21	22.9
Brain	11	7.4	6	4.2	6	7.9	11	14.7	7	6.8	5	6.2	4	6.1
Breast	2	1.1	1	0.7	1	1.2	3	1.4	0	1.3	1	0.9	0	1.0
Cervix	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Colon	34	27.8	21	16.8	23	28.3	36	39.4	19	26.4	25	20.2	16	20.1
Endometrium	_			-	-	-0.0	-	-	-				-	
Esophagus	7	8.5	2	5.0	11	7.1	11	12.2	6	7.2	7	5.7	5	5.8
Hodgkin's lymphoma	5	2.2	1	1.8	1	3.3	8	4.4	2	2.6	0	2.7	3	2.3
Kidney and renal pelvis	9	13.4	7	7.3	11	11.8	22	17.0	9	11.0	8	9.2	11	8.5
Larynx	4	5.4	7	2.6*	3	5.3	5	7.6	6	4.3	5	3.6	2	3.8
Leukemia	14	12.2	10	7.1	13	12.5	17	18.8	12	11.2	8	9.7	7	9.4
Liver & bile duct	4	3.5	10	2.2	4	3.2	5	5.1	4	2.9	1	2.8	3	2.4
Lung and bronchus	73	67.4	37	40.7	79	61.4+	98	88.3	61	58.8	27	51.9*	40	47.3
Melanoma of skin	28	20.6	11	12.4	10	22.1*	36	33.0	22	17.9	13	16.3	10	16.3
IVICIATIONIA OF SKIT	20	20.0	'''	12.7	10	22.1	30	55.0		17.5	'	10.5	'0	10.5
Myeloma	7	5.1	3	3.3	5	5.1	7	7.1	4	4.9	3	4.0	3	3.7
Non-Hodgkin's lymphoma	25	17.4	7	11.1	23	17.0	25	28.6	12	16.8	13	13.8	11	13.5
Oral cavity and pharynx	20	15.3	0	10.1*	11	15.4	19	23.3	20	12.5+	14	11.1	7	11.4
Ovary	-	-	-	-	-	-	-	-	-	-	-	-	-	_ '
Pancreas	9	6.5	2	4.3	8	6.3	11	8.9	5	6.2	4	5.1	3	5.0
Prostate	138	156.5	98	88.0	106	147.8*	238	189.3*	128	130.7	81	112.1*	89	105.2
Rectum & rectosigmoid	16	13.6	3	8.6	11	13.2	17	19.1	15	11.4	10	9.9	11	9.2
Stomach	4	5.5	4	2.9	9	4.0+	3	8.4	1	5.0	5	3.6	5	3.4
Testis	5	5.8	2	3.5	3	6.6	18	10.3+	6	5.0	5	4.9	4	5.1
Thyroid	3	2.2	1	1.3	1	2.3	1	5.3	2	1.9	2	1.6	5	1.3*

Note: Observed and expected numbers exclude in-situ cases, basal/squamous skin cases, and cases with unknown age and/or gender.

⁺ Statistically significant difference at p=0.05 or less.

^{*} Statistically significant difference at p=0.01 or less.

2000 OBSERVED VERSUS EXPECTED NUMBERS BY HEALTH DISTRICT

FEMALES

	HD 1		HD 2		HD 3		Н	1D 4	Н	ID 5	Н	ID 6	Н	ID 7
	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP	OBS	EXP
All Sites	453	378.3*	201	224.5	360	385.3	663	577.1*	309	345.8+	230	297.4*	262	277.8
Bladder	12	7.7	3	5.2	7	8.8	15	11.6	5	8.0	8	6.0	4	6.1
Brain	2	5.6	2	2.9	4	5.4	13	7.0+	2	4.9	3	4.2	8	3.3*
Breast	139	128.5	67	73.0	112	126.5		192.4+	112	111.4	83	96.6	87	92.0
Cervix	6	6.2	5	3.0	5	5.7	10	10.4	8	4.6	2	4.7	3	4.6
Colon	37	32.2	20	19.8	40	32.2	47	49.1	25	30.7	17	25.7	26	22.3
Endometrium	27	20.7	11	12.3	22	20.5	34	32.4	17	18.9	11	16.4	13	15.5
Esophagus	6	2.2+	3	1.6	3	2.8	3	4.3	2	2.6	0	2.4	1	2.1
Hodgkin's lymphoma	2	1.0	0	0.7	1	1.2	2	2.2	2	0.8	0	1.1	1	0.9
Kidney and renal pelvis	9	8.8	6	4.9	10	8.4	14	12.9	8	7.6	5	6.8	4	6.6
Larynx	1	0.4	0	0.3	0	0.5	1	0.6	0	0.5	ı	0.3	l	0.4
Leukemia	12	7.5	3	5.0	10	8.3	14	12.6	7	7.6	l	7.1	l	6.1
Liver & bile duct	3	1.3	2	0.8	1	1.6	1	2.8	2	1.3	1	1.2	0	1.3
Lung and bronchus	67	38.7*	33	24.3	33	44.6	82	56.9*	25	40.6+	14	34.2*	20	31.2+
Melanoma of skin	20	13.5	6	8.1	17	13.3	26	23.1	8	13.0	5	11.6	5	11.3
Myalama	4	2.0	4	2.2	2	2.0	11	3.6*	3	3.2		2.9	,	0.7
Myeloma	4	3.6	1		15	3.9	26	27.1	l .		1 18		1 14	2.7
Non-Hodgkin's lymphoma	17	17.6	8	10.3		17.8			14	15.8 6.2	'	12.5	l	12.3
Oral cavity and pharynx	8	7.5	3	4.5	6	7.5	9	12.4	9		5	5.6	3	5.6
Ovary	9	16.4	6	8.6	19	13.9	25	24.5	9	13.6	20	10.2*	10	11.0
Pancreas	11	7.0	0	5.1+	3	8.6	13	10.9	10	6.3	5	5.8	7	5.0
Prostate	_	_	_	-	_	-	_	_	_	_	_	_	_	_
Rectum & rectosigmoid	10	11.5	7	6.4	16	10.1	14	17.1	11	9.7	2	9.0+	11	7.4
Stomach	9	4.0+	2	2.8	3	5.0	4	7.7	3	4.4	4	3.4		3.2
Testis	_	-	_		_	-	_	-	_	-	-	-		-
Thyroid	8	10.3	5	5.8	5	10.8	30	14.6*	10	8.4	5	8.6	6	8.4

Note: Observed and expected numbers exclude in-situ cases, basal/squamous skin cases, and cases with unknown age and/or gender.

⁺ Statistically significant difference at p=0.05 or less.

^{*} Statistically significant difference at p=0.01 or less.

SECTION VI

RISKS OF DEVELOPING AND DYING FROM CANCER

For Females

If your current	The	n your risk o	f <u>developing</u>	cancer by a	particular ag	e is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 82	1 in 23	1 in 9.6	1 in 4.8	1 in 3	1 in 2.3
40		1 in 31	1 in 11	1 in 5	1 in 3.1	1 in 2.3
50			1 in 15	1 in 5.7	1 in 3.3	1 in 2.4
60				1 in 8.3	1 in 3.8	1 in 2.6
70					1 in 5.7	1 in 3
80						1 in 4.3*

If your current	The	n your risk o	f dying from	cancer by a	particular ag	e is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 490	1 in 124	1 in 38	1 in 15	1 in 8	1 in 5
40		1 in 164	1 in 41	1 in 15	1 in 8	1 in 5
50			1 in 54	1 in 17	1 in 8.3	1 in 5.1
60				1 in 23	1 in 9.5	1 in 5.4
70					1 in 14	1 in 6.3
80						1 in 8.6*

For Males

If your current	The	n your risk o	f <u>developing</u>	cancer by a	particular ag	e is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 136	1 in 40	1 in 12	1 in 4.5	1 in 2.5	1 in 2
40		1 in 56	1 in 13	1 in 4.5	1 in 2.5	1 in 1.9
50			1 in 16	1 in 4.7	1 in 2.5	1 in 1.9
60				1 in 5.9	1 in 2.7	1 in 2
70					1 in 3.5	1 in 2.2
80						1 in 2.8*

If your	The	n your risk o	f <u>dying from</u>	cancer by a	particular ag	e is:
current						
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 812	1 in 151	1 in 41	1 in 14	1 in 6.4	1 in 4.2
40		1 in 183	1 in 42	1 in 14	1 in 6.4	1 in 4.1
50			1 in 54	1 in 14	1 in 6.4	1 in 4.1
60				1 in 18	1 in 6.9	1 in 4.2
70					1 in 9.2	1 in 4.5
80						1 in 5.7*

Female Breast Cancer

If your current	Then yo	our risk of <u>de</u>	veloping bre	east cancer by	y a particular	age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 260	1 in 57	1 in 23	1 in 13	1 in 8.8	1 in 7.2
40		1 in 72	1 in 25	1 in 13	1 in 9	1 in 7.3
50			1 in 38	1 in 16	1 in 10	1 in 7.9
60				1 in 26	1 in 13	1 in 9.3
70					1 in 21	1 in 12
80						1 in 22*

If your current	Then y	our risk of <u>dy</u>	ring from bre	ast cancer by	y a particular	age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 1803	1 in 401	1 in 138	1 in 72	1 in 45	1 in 31
40		1 in 512	1 in 148	1 in 75	1 in 46	1 in 31
50			1 in 206	1 in 86	1 in 50	1 in 32
60				1 in 142	1 in 63	1 in 37
70					1 in 102	1 in 44
80						1 in 59*

Prostate Cancer

If your current	Then yo	ur risk of <u>dev</u>	eloping pros	state cancer	by a particula	ar age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 14665	1 in 533	1 in 52	1 in 14	1 in 7.4	1 in 6
40		1 in 544	1 in 51	1 in 13	1 in 7.3	1 in 5.9
50			1 in 54	1 in 13	1 in 7.1	1 in 5.8
60				1 in 16	1 in 7.6	1 in 6
70					1 in 11	1 in 7.5
80						1 in 13*

If your current	Then yo	ur risk of <u>dyi</u>	ng from pros	state cancer b	oy a particula	ar age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in *	1 in 22562	1 in 1600	1 in 230	1 in 65	1 in 26
40		1 in 22191	1 in 1574	1 in 227	1 in 64	1 in 26
50			1 in 1646	1 in 223	1 in 63	1 in 25
60				1 in 242	1 in 61	1 in 24
70					1 in 69	1 in 22
80						1 in 21*

Colon/Rectal Cancer in Females

If your current	Then your	risk of <u>deve</u>	loping colon	rectal cance	r by a particu	ılar age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 2747	1 in 603	1 in 159	1 in 58	1 in 29	1 in 18
40		1 in 765	1 in 168	1 in 58	1 in 29	1 in 18
50			1 in 211	1 in 62	1 in 29	1 in 18
60				1 in 84	1 in 33	1 in 19
70					1 in 47	1 in 21
80						1 in 29*

If your current	Then your	risk of <u>dying</u>	g from colon	rectal cance	r by a particu	ılar age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 10505	1 in 2338	1 in 525	1 in 208	1 in 96	1 in 45
40		1 in 2981	1 in 548	1 in 210	1 in 96	1 in 45
50			1 in 661	1 in 222	1 in 97	1 in 45
60				1 in 322	1 in 110	1 in 46
70					1 in 148	1 in 48
80						1 in 53*

Colon/Rectal Cancer in Males

If your current	Then your	risk of <u>deve</u>	loping colon	rectal cance	r by a particu	ılar age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 2608	1 in 465	1 in 134	1 in 47	1 in 25	1 in 18
40		1 in 557	1 in 139	1 in 47	1 in 24	1 in 18
50			1 in 180	1 in 50	1 in 25	1 in 18
60				1 in 64	1 in 27	1 in 18
70					1 in 39	1 in 21
80						1 in 30*

If your	Then your	risk of <u>dying</u>	from colon	rectal cance	<mark>r</mark> by a particւ	ılar age is:
current						
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 14665	1 in 1786	1 in 426	1 in 142	1 in 67	1 in 40
40		1 in 2001	1 in 431	1 in 141	1 in 66	1 in 40
50			1 in 534	1 in 148	1 in 67	1 in 40
60				1 in 192	1 in 72	1 in 40
70					1 in 96	1 in 43
80						1 in 49*

Melanoma in Females

If your current	Then	your risk of <u>c</u>	developing m	nelanoma by	a particular a	age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 836	1 in 306	1 in 178	1 in 113	1 in 84	1 in 68
40		1 in 477	1 in 223	1 in 129	1 in 92	1 in 73
50			1 in 412	1 in 174	1 in 113	1 in 85
60				1 in 287	1 in 148	1 in 103
70					1 in 273	1 in 142
80						1 in 221*

If your current	Then	your risk of	dying from m	elanoma by	a particular a	ige is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 23022	1 in 5762	1 in 1875	1 in 1243	1 in 658	1 in 427
40		1 in 7619	1 in 2024	1 in 1303	1 in 672	1 in 431
50			1 in 2712	1 in 1546	1 in 725	1 in 450
60				1 in 3449	1 in 949	1 in 517
70					1 in 1169	1 in 543
80						1 in 761*

Melanoma in Males

If your current	Then	your risk of <u>c</u>	developing m	nelanoma by	a particular a	age is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 707	1 in 287	1 in 138	1 in 82	1 in 59	1 in 48
40		1 in 475	1 in 169	1 in 91	1 in 63	1 in 51
50			1 in 254	1 in 110	1 in 70	1 in 55
60				1 in 180	1 in 91	1 in 66
70					1 in 153	1 in 88
80						1 in 131*

If your current	Then	your risk of	dying from m	elanoma by	a particular a	ige is:
age is:	By age 40	By age 50	By age 60	By age 70	By age 80	Ever
30	1 in 7852	1 in 2066	1 in 1058	1 in 563	1 in 345	1 in 251
40		1 in 2758	1 in 1202	1 in 596	1 in 355	1 in 255
50			1 in 2070	1 in 739	1 in 395	1 in 273
60				1 in 1079	1 in 459	1 in 295
70					1 in 670	1 in 342
80						1 in 445*

REFERENCES

- 1. Percy C, Van Holten V, Muir C. *International Classification of Diseases for Oncology*. 2nd ed. Geneva, Switzerland: World Health Organization; 1990.
- 2. Shambaugh EM, Weiss MA (eds). Summary Staging Guide for the Cancer Surveillance, Epidemiology and End Results Reporting (SEER) Program. National Institutes of Health; 1986.
- 3. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ (eds). *Manual for Staging of Cancer*. 5th ed. American Joint Committee on Cancer; 1997.
- 4. Data Standards and Data Dictionary, Fourth Edition. North American Association of Central Cancer Registries; 1999. (Standard for Cancer Registries; vol. 2.)
- 5. Cunningham J, Hankey B, Lyles B, Percy C, Ries L, Seiffert J, Shambaugh E, Van Holten V (eds). SEER Program Code Manual, rev. ed., Cancer Statistics Branch, National Cancer Institute; 1992.
- 6. Commission on Cancer. *Registry Operations and Data Standards (ROADS)*. Chicago: American College of Surgeons; 1998.
- 7. U.S. Bureau of the Census, Census 2000 Data on American FactFinder. Internet Release Date: August 01, 2001.
- 8. Annual Report of the Washington State Cancer Registry. *1993 Cancer Incidence in Washington*. Washington State Department of Health; 1996.
- 9. Murphy GP, Lawrence W, Lenhard RE. *American Cancer Society Textbook of Clinical Oncology*. The American Cancer Society, Inc.: Atlanta; 1995.
- 10. Ninth Report on Carcinogens, U.S. Department of Health and Human Services, National Toxicology Program; 2000.
- 11. SEER*Stat, SEER Cancer Incidence Public-Use Database, 1973-1998, Version 4.1. National Cancer Institute; 2001.
- 12. DEVCAN: Probability of Developing or Dying of Cancer Software, Version 4.1. Feuer EJ, Wun LM, National Cancer Institute; 2001.
- 13. Preliminary 2000 mortality data, Bureau of Vital Records and Health Statistics, Idaho Department of Health and Welfare; October 9, 2001.
- 14. Seiffert JE (ed). Standards for Completeness, Quality, Analysis, and Management of Data. American Association of Central Cancer Registries; 1994. (Standards for Cancer Registries; vol. 3.)

APPENDICES

APPENDIX A

STANDARD SITE ANALYSIS CATEGORIES

SITE CATEGORY	PRIMARY SITE CODE (ICD-O-2)
Categories in SMALL CAPITALS are aggregated from groups indented under them	EXCLUDES histologic types 9590-9989
BUCCAL CAVITY & PHARYNX	
Lip	000 - 009
Tongue	019 - 029
Salivary Glands	079 - 089
Floor of Mouth	040 - 049
Gum and Other Mouth	030 - 039 050 - 059 060 - 069
Nasopharynx	110 - 119
Tonsil	090 - 099
Oropharynx	100 - 109
Hypopharynx	129 130 - 139 141
Other Buccal Cavity and Pharynx	140 142-148
DIGESTIVE SYSTEM	
Esophagus	150 - 159
Stomach	160 - 169
Small Intestine	170 - 179
COLON (excluding rectum)	
Cecum	180
Appendix	181
Ascending Colon	182
Hepatic Flexure	183
Transverse Colon	184
Splenic Flexure	185
Descending Colon	186
Sigmoid Colon	187
Large Intestine, NOS	188 - 189 260

SITE CATEGORY	PRIMARY SITE CODE (ICD-O-2)			
Categories in SMALL CAPITALS are aggregated from groups indented under them	EXCLUDES histologic types 9590-9989			
RECTUM AND RECTOSIGMOID				
Rectosigmoid Junction	199			
Rectum	209			
Anus, Anal Canal, & Anorectum	210 - 212 218			
Liver	220			
Intrahepatic Bile Duct	221			
Gallbladder	239			
Other Biliary	240 - 249			
Pancreas	250 - 259			
Retroperitoneum	480			
Peritoneum, Omentum, & Mesentery	481 - 482			
Other Digestive Organs	268 - 269 488			
RESPIRATORY SYSTEM				
Nasal Cavity, Middle Ear, & Accessory Sinuses	300 - 301 310 - 319			
Larynx	320 - 329			
Lung and Bronchus	340 - 349			
Pleura	384			
Trachea, Mediastinum, & Other Respiratory Organs	339 381 - 383 388 390 398 399			
BONES AND JOINTS	400 - 419			

SITE CATEGORY	PRIMARY SITE CODE (ICD-O-2)			
Categories in SMALL CAPITALS are aggregated from groups indented under them	EXCLUDES histologic types 9590-9989			
SKIN (Excluding Basal and Squamous)				
Melanomas - Skin	440 - 449 Histology Types 8720 - 8790 ONLY			
Other Non - Epithelial	440 - 449 Also Excluding Histology Types 8000 - 8004 8010 - 8012 8070 - 8076 8090 - 8096 8720 - 8790 9590 - 9989			
BREAST	500 - 509			
FEMALE GENITAL SYSTEM				
Cervix Uteri	530 - 539			
Corpus Uteri	540 - 549			
Uterus, NOS	559			
Ovary	569			
Vagina	529			
Vulva	510 - 519			
Other Female Genital Organs	570 - 589			
MALE GENITAL SYSTEM				
Prostate	619			
Testis	620 - 629			
Penis	600 - 609			
Other Male Genital Organs	630 - 639			
URINARY SYSTEM				
Bladder	670 - 679			
Kidney and Renal Pelvis	649 659			
Ureter	669			
Other Urinary Organs	680 - 689			
EYE AND ORBIT	690 - 699			

Page 88

SITE CATEGORY	PRIMARY SITE CODE
Categories in SMALL CAPITALS are aggregated from groups indented under them	EXCLUDES histologic types 9590-9989
BRAIN AND OTHER NERVOUS SYSTEM	
Brain	710 - 719 Also excludes: 953
Other Nervous System	A) 710 - 719 (meningioma) Histologic Type: 9530-9539 ONLY B) 700 - 709 C) 720 - 729
ENDOCRINE SYSTEM	
Thyroid	739
Other Endocrine (including Thymus)	379 740 - 749 750 - 759

SITE CATEGORY Categories in SMALL CAPITALS are aggregated from groups indented under them	PRIMARY SITE CODE	HISTOLOGY
LYMPHOMAS		
Hodgkin's Disease		
Nodal	024, 098, 099, 111, 142, 379 422 770 - 779	Types: 9650 - 9667 ONLY
Extranodal	For All Other Sites	Types: 9650 - 9667 ONLY
Non - Hodgkin's Disease		
Nodal	024, 098, 099, 111, 142, 379, 422 770 - 779	Types: 9590 - 9595 9670 - 9719 ONLY
Extranodal	For All Other Sites Excluding Sites: 024, 098, 099, 111, 142, 379, 422 770 - 779	Types: 9590 - 9595 9670 - 9719 ONLY
MULTIPLE MYELOMA	For All Sites	Types: 9731 - 9732 ONLY

SITE CATEGORY	HISTOLOGY
Categories in SMALL CAPITALS are aggregated from groups indented under them	
LEUKEMIAS	
Lymphocytic	
Acute Lymphocytic	Type: 9821, 9828, ONLY
Chronic Lymphocytic	Type: 9823 ONLY
Other Lymphocytic	Type: 9820, 9822, 9824, 9825, 9826, ONLY
Granulocytic (Myeloid)	
Acute Granulocytic	Type: 9861, 9867, 9871, 9872, 9873, 9874, ONLY
Chronic Granulocytic	Type: 9863, 9868, ONLY
Other Granulocytic	Type: 9860, 9862, 9864, 9866, ONLY
Monocytic	
Acute Monocytic	Type: 9891 ONLY
Chronic Monocytic	Type: 9893 ONLY
Other Monocytic	Туре:
	9890, 9892, 9894, ONLY
Other	
Other Acute	Type: 9801, 9841, ONLY
Other Chronic	Type: 9803, 9842, 9931, ONLY
Aleukemic, Subleukemic, and NOS	Type: 9800, 9802, 9804, 9827, 9830, 9840, 9850, 9870, 9880, 9900, 9910, 9930 - 9941 ONLY

SITE CATEGORY	PRIMARY SITE CODE		
Categories in SMALL CAPITALS are aggregated from groups indented under them	EXCLUDES histologic types 9590-9989		
ILL- DEFINED AND UNSPECIFIED SITES	A) Type: 9720 - 9723 9740 9741 9760 - 9764 9950 - 9989 ONLY For All Sites B) 760 - 768 809 Type 8000 - 9589 ONLY C) 420 - 424 Type 8000 - 9589 ONLY D) 770 - 779 Type 8000 - 9589 ONLY		
INVALID SITE	Site or histology code not within valid range or site code not found in this table.		

Source: "Standards for Completeness, Quality, Analysis, and Management of Data, Vol III". American Association of Central Cancer Registries. 14

APPENDIX B

2000 U.S. STANDARD POPULATION

AGE GROUP	United States 2000 Standard Million Population
	_
0-4	69,135
5-9	72,533
10-14	73,032
15-19	72,169
20-24	66,478
25-29	64,529
30-34	71,044
35-39	80,762
40-44	81,851
45-49	72,118
50-54	62,716
55-59	48,454
60-64	38,793
65-69	34,264
70-74	31,773
75-79	26,999
80-84	17,842
85 +	15,508
Total	1,000,000

Source: SEER Program, National Cancer Institute, 2001. 11

APPENDIX C
2000 POPULATION BY HEALTH DISTRICT, GENDER, AND AGE GROUP

	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	STATE
Males								
< 5	5,971	2,867	8,289	13,361	6,317	6,720	6,522	50,047
5 to 9	6,700	3,206	8,501	13,439	6,572	6,574	6,868	51,860
10 to 14	7,330	3,391	8,060	13,354	6,962	7,177	7,423	53,697
15 to 19	7,016	4,695	8,016	12,944	7,317	7,542	8,601	56,131
20 to 24	4,757	5,107	6,512	13,533	5,381	6,248	7,396	48,934
25 to 29	4,925	3,474	6,634	14,469	4,959	5,177	4,479	44,117
30 to 34	5,303	3,024	6,479	14,376	4,979	4,508	4,442	43,111
35 to 39	6,383	3,358	6,860	15,176	5,798	4,972	5,393	47,940
40 to 44	6,998	3,684	6,564	14,452	6,172	5,552	5,727	49,149
45 to49	7,208	3,715	6,112	12,757	5,748	5,382	5,368	46,290
50 to 54	6,537	3,281	5,320	10,751	4,838	4,429	4,343	39,499
55 to 59	4,964	2,586	4,319	7,348	3,924	3,349	3,459	29,949
60 to 64	4,154	2,245	3,507	5,179	3,168	2,782	2,740	23,775
65 to 69	3,416	1,849	2,894	4,116	2,665	2,333	2,189	19,462
70 to 74	2,885	1,659	2,557	3,408	2,370	2,018	1,871	16,768
75 to 79	2,031	1,340	2,167	2,753	1,944	1,524	1,521	13,280
80 to 84	1,286	906	1,412	1,750	1,389	1,022	905	8,670
85+	909	632	1,054	1,161	966	702	557	5,981
Total	88,773	51,019	95,257	174,327	81,469	78,011	79,804	648,660
	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	STATE
Females								
Females < 5	5,639	2,710	7,970	12,895	5,903	6,302	6,177	47,596
	5,639 6,220	2,710 2,973	7,970 8,025	12,895 12,599	5,903 6,312	6,302 6,340	6,177 6,427	47,596 48,896
< 5								
< 5 5 to 9	6,220	2,973	8,025	12,599	6,312	6,340	6,427	48,896
< 5 5 to 9 10 to 14	6,220 6,839	2,973 3,311	8,025 7,722	12,599 12,510	6,312 6,663	6,340 6,828	6,427 7,038	48,896 50,911
< 5 5 to 9 10 to 14 15 to 19	6,220 6,839 6,437	2,973 3,311 4,251	8,025 7,722 7,375	12,599 12,510 12,441	6,312 6,663 6,641	6,340 6,828 7,389	6,427 7,038 10,193	48,896 50,911 54,727
< 5 5 to 9 10 to 14 15 to 19 20 to 24	6,220 6,839 6,437 4,599	2,973 3,311 4,251 4,340	8,025 7,722 7,375 6,366	12,599 12,510 12,441 12,343	6,312 6,663 6,641 4,746 4,659 4,824	6,340 6,828 7,389 6,386	6,427 7,038 10,193 6,280	48,896 50,911 54,727 45,060
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39	6,220 6,839 6,437 4,599 4,874 5,473 6,652	2,973 3,311 4,251 4,340 2,840 2,787 3,353	8,025 7,722 7,375 6,366 6,499 6,116 6,711	12,599 12,510 12,441 12,343 12,721 12,965 14,062	6,312 6,663 6,641 4,746 4,659 4,824 5,694	6,340 6,828 7,389 6,386 5,049 4,550 5,183	6,427 7,038 10,193 6,280 4,369	48,896 50,911 54,727 45,060 41,011 41,194 46,973
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to49	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144	12,599 12,510 12,441 12,343 12,721 12,965 14,062	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to49 50 to 54	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64 65 to 69	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955 3,408	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049 1,930	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634 3,151	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391 4,540	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243 2,942	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784 2,493	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674 2,243	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730 20,707
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64 65 to 69 70 to 74	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955 3,408 3,018	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049 1,930 1,742	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634 3,151 3,065	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391 4,540 4,111	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243 2,942 2,759	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784 2,493 2,152	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674 2,243 2,186	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730 20,707 19,033
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64 65 to 69 70 to 74 75 to 79	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955 3,408 3,018 2,645	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049 1,930 1,742 1,605	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634 3,151 3,065 2,738	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391 4,540 4,111 3,904	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243 2,942 2,759 2,408	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784 2,493 2,152 2,007	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674 2,243 2,186 1,856	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730 20,707 19,033 17,163
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64 65 to 69 70 to 74 75 to 79 80 to 84	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955 3,408 3,018 2,645 1,827	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049 1,930 1,742 1,605 1,254	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634 3,151 3,065 2,738 2,123	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391 4,540 4,111 3,904 2,840	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243 2,942 2,759 2,408 1,921	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784 2,493 2,152 2,007 1,515	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674 2,243 2,186 1,856 1,296	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730 20,707 19,033 17,163 12,776
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64 65 to 69 70 to 74 75 to 79 80 to 84 85+	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955 3,408 3,018 2,645 1,827 1,781	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049 1,930 1,742 1,605 1,254 1,300	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634 3,151 3,065 2,738 2,123 2,014	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391 4,540 4,111 3,904 2,840 2,663	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243 2,942 2,759 2,408 1,921 1,764	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784 2,493 2,152 2,007 1,515 1,397	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674 2,243 2,186 1,856 1,296 1157	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730 20,707 19,033 17,163 12,776 12,076
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64 65 to 69 70 to 74 75 to 79 80 to 84	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955 3,408 3,018 2,645 1,827	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049 1,930 1,742 1,605 1,254	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634 3,151 3,065 2,738 2,123	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391 4,540 4,111 3,904 2,840	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243 2,942 2,759 2,408 1,921	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784 2,493 2,152 2,007 1,515	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674 2,243 2,186 1,856 1,296	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730 20,707 19,033 17,163 12,776
< 5 5 to 9 10 to 14 15 to 19 20 to 24 25 to 29 30 to 34 35 to 39 40 to 44 45 to 49 50 to 54 55 to 59 60 to 64 65 to 69 70 to 74 75 to 79 80 to 84 85+	6,220 6,839 6,437 4,599 4,874 5,473 6,652 7,468 7,396 6,359 4,970 3,955 3,408 3,018 2,645 1,827 1,781	2,973 3,311 4,251 4,340 2,840 2,787 3,353 3,724 3,596 3,122 2,627 2,049 1,930 1,742 1,605 1,254 1,300	8,025 7,722 7,375 6,366 6,499 6,116 6,711 6,555 6,144 5,344 4,488 3,634 3,151 3,065 2,738 2,123 2,014	12,599 12,510 12,441 12,343 12,721 12,965 14,062 13,901 12,686 10,165 7,291 5,391 4,540 4,111 3,904 2,840 2,663	6,312 6,663 6,641 4,746 4,659 4,824 5,694 6,002 5,654 4,918 3,875 3,243 2,942 2,759 2,408 1,921 1,764	6,340 6,828 7,389 6,386 5,049 4,550 5,183 5,636 5,201 4,341 3,342 2,784 2,493 2,152 2,007 1,515 1,397	6,427 7,038 10,193 6,280 4,369 4,479 5,318 5,620 5,205 4,328 3,482 2,674 2,243 2,186 1,856 1,296 1157	48,896 50,911 54,727 45,060 41,011 41,194 46,973 48,906 45,882 38,577 30,075 23,730 20,707 19,033 17,163 12,776 12,076

Source: U.S. Bureau of the Census, 2001.